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ABSTRACT 
There is evidence from earlier studies that oral contraceptive pills may be a risk factor for certain 
chronic diseases, including heart disease, stroke, and breast cancer. Previous studies mainly focus 
on the estrogen component of combined (estrogen+ progestin) oral contraceptives (COCs) due to 
their popularity. This focus limits our understanding of progestin-only contraceptives and its 
relationship to commonly occurring chronic diseases. To provide insight into alternative methods 
of oral contraception, this dissertation explores the relationship between progestin-only oral 
contraceptive (POC) pills and heart disease, stroke, and breast cancer. We hypothesize that women 
using POCs are less likely to have certain chronic diseases compared to women using COCs.  
       We conducted a retrospective cohort study using Medicaid data for 2000-2013 to (1) examine 
trends in OC medication use over time, (2) determine the association between the type of OC use 
and breast cancer mortality, and (3) compare estrogen+ progestin formulations with progestin-only 
regimens to understand the association of OC types and cardiovascular disease. We found an 
increasing trend of POC and POC+COC use in the Medicaid population from 2000 to 2013, which 
could reflect increased knowledge of POCs. However, COCs are still prescribed much more 
frequently than any other contraceptive method.  
       In further investigations, we found evidence that women using POCs had a significantly 
reduced risk of breast cancer mortality whereas women using COCs had an increased risk. 
Similarly, POCs decreased the risk of heart disease compared to COC use. Conversely, the 
relationship between POCs and stroke was more abstruse. All analyses were stratified by race to 
explore differences in oral contraceptive use among African American and European American
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 women in the South Carolina Medicaid registry. We aimed to study a population that is typically 
under-represented in the scientific literature.  
       The findings of this study suggest that there may be beneficial effects of using POCs in lieu of 
COCs to reduce estrogen-related complications of oral contraceptives. Additional studies are 
required to provide conclusive evidence.  
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CHAPTER I 
INTRODUCTION 
1.1 Study Objective  
The objective of this dissertation is to examine the relationship between oral contraceptive use, 
progesterone-only or combined oral contraceptive pills, and the subsequent incidence of heart 
disease and stroke, as well as breast cancer mortality, in a cohort of South Carolinian women 
participating in Medicaid, a low-cost health care coverage program for individuals meeting income 
guidelines. This study will provide additional information about various types of oral 
contraceptives and further explain the benefits and drawbacks of progesterone-only contraceptive 
pills.  
1.2 Statement of the problem   
       In the United States (US), chronic diseases have a substantial effect on women’s overall health 
and quality of life. Cardiovascular diseases (CVDs) and cancer are the leading causes of mortality 
in females living in South Carolina (SC) and the US (ISCD, 2015).  The predominant causes of 
CVD deaths are coronary heart disease (CHD) and stroke (Go et al. 2013), and of cancer deaths:  
lung and breast cancer (Torre et al. 2015). A reduction in these fatalities is of great public health 
importance.  
       Public health researchers aim to control chronic diseases by early detection and prevention 
methods, and by addressing etiologic causes of the problem. CVDs are one of the most preventable 
diseases (Labarthe, 2011) that continue to plague our society. To improve the health of families, 
we must promote healthy lifestyles and reduce population exposures to adverse agents.  The role 
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of oral contraceptives (OCs) as a possible risk factor for CHD, stroke, and breast cancer incidence 
and mortality has long been demonstrated in estrogen-dominant OCs (Marchbanks et al., 2002; 
Bousser et al., 2000; Wynn, 1991). 
       Current guidelines conclude that contraceptive’s benefits outweigh the potential risks (FSRH, 
2011; Bousser et al., 2000); yet, these recommendations neglect to thoroughly consider 
demographic populations that are at a higher risk for CVD and cancer death. Furthermore, risk 
factors for chronic diseases, such as unhealthy diet, sedentary behavior, obesity, and raised blood 
glucose, are becoming more prevalent in our society and may cause women to suffer greater disease 
burden in the future (Shufelt et al., 2009). Studies show that low-income women are more likely to 
experience a negative contraceptive counseling experience, be pressured by a healthcare clinician 
to use a contraceptive method, and to feel that the family planning service was not tailored to their 
needs and preferences (Becker et al., 2003;, Yee et al., 2011). This perception may cause patients 
to share less information with their doctor and increase the chances of combined OC use in women 
who smoke, partake in less physical activity, and engage in other unhealthy behaviors. The 
prevention of unintended pregnancies through the use of estrogen-containing OCs may have 
adverse implications for the incidence and treatment of CVD and breast cancer. Thus, it is important 
to identify high-risk populations that may benefit from an alternative contraceptive method. 
       The effects of exogenous estrogen on the body’s system have been studied in much greater 
detail than the effects of exogenous progesterone. The estrogen component of OCs is associated 
with nausea, vomiting, and several more severe adverse drug reactions (ADRs): an excess risk of 
venous thromboembolism (VTEs) (4.3- 16/ 100,000 woman-years) (FDA, 2015), cardiovascular 
death (1.5-4.8/ 100,000) (WHO 1996; Peck, 2012), and an increase risk breast cancers (Vesna et 
al., 2010). Among smokers, the excess risk associated with combined OCs is 400/100,000 woman-
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years (Peck, 2012). Total medical ADRs are estimated to cause approximately 1.5 million 
hospitalizations and 118 000 deaths in the US (IoM, 2006).  
       Calculating the intermediate and long-term events related to the use of OCs is challenging. 
Health care professionals and federal governing agencies have difficulty detecting, reporting, 
and/or analyzing ADRs related to drug use due to incomplete or inaccurate data, cost, and non-
standardized source of data (Darzen, 2007; Thomas et al., 2003) In addition, external factors, such 
as biological and environmental factors, may modify the relationship between OCs and the 
incidence, prevalence, and death rate of females (STAT, 2000). 
       The relationship between OC exposure and certain chronic disease outcomes have sparked 
research around combined estrogen + progestin OCs. The majority of studies support exogenous 
estrogen’s potential to increase the risk of CVDs and breast cancer (Murphy, 2011; Pezzini et al., 
2007). To our knowledge, no studies shown a negative effect of exogenous progesterone on breast 
cancer and few studies have examined progesterone-only contraceptive pills (POCs) and these 
chronic disease outcomes. 
       A viable alternative to estrogen-containing pills for preventing unwanted pregnancies is 
critically important for women who already suffer from elevated risks. Healthy People (HP) 2020 
aims to increase the proportion of sexually active women who receive reproductive health services 
to approximately 90% by 2020 (HP 2020, 2015), which, if successful, will further increase the 
number of women receiving OCs. With the risk of cardiovascular disease and breast cancer 
increasing, it is important to understand the impact that combined OC pills may pose on health for 
high-risk groups; estrogen-free pills may be a safer alternative. 
       In the US, vulnerable populations include women of certain age groups, race/ethnicity, 
geographic demarcations, urban-rural classifications, and low socioeconomic (SES) status. In terms 
of OC use, it is important to target women older than 35; minorities; the southeastern region of the 
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US; rural populations; and women who lack access to education, economic stability, safe 
neighborhoods, and to adequately built environments (Cole et al., 2007). 
       SC is a “region of extreme disparities,”(Levin et al. 2001) located in the southeastern part of 
the US. Despite a recent 34% drop in CVD mortality rates, SC has a higher age-adjusted mortality 
rate than the US (Khosrow, 2010).  In addition, SC has more than twice the percentage of African 
Americans (AAs) than the US overall (US Census Bureau, 2015).  Studying SC can help us 
understand why AAs are 30% more likely to die from heart disease than the European American 
(EA) population (Khosrow, 2010).  As a part of the “Stroke Belt,” SC has a higher percentage of 
stroke among adults compared to other states (3.1% vs. 2.4%, excluding people in long-term 
facilities) (Khosrow, 2010). Using the SC Medicaid cohort will improve our assessment of 
vulnerable populations and help us determine if the type of OC women use poses a great risk for 
breast cancer, stroke (Guidetti et al., 2014) and CHD (US Census Bureau, 2015; Cunningham et 
al., 2013; Boan et al., 2014; Cooper et al., 2000). 
1.3 Significance  
       Approximately 70 million women in the US are in their childbearing years (15-44) (Dye, 2008) 
and more than 99% of women participating in sexual intercourse have used at least one 
contraception method; contraceptive pills and sterilization are the most common types of methods 
used (Rothman, et al., 2008; Glaser et al., 2009).  With the high demand of OCs, researchers must 
continue to examine healthier alternatives to estrogen-containing OC pills for pregnancy prevention 
and family planning. 
       The associations between combined oral contraceptive pills (COCs) and breast cancer 
(Nguyen, et al., 2007; ,Kumle et al., 2002), venous thromboembolic events (Maxwell et al., 2014; 
,Spencer, et al., 2009) , high blood pressure (FSRH, 2011), a temporary reduction in fecundity 
(FSRH, 2011), depression (FSRH, 2011), nausea (FSRH, 2011; ,Spencer, et al. 2009) headaches 
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(Spencer, et al., 2009), heart attack (FSRH, 2011), myocardial infarction (MI) and stroke (Spencer 
et al., 2009) have been established previously. To our knowledge, the relationship between POCs, 
breast cancer, and CVDs in vulnerable groups has not yet been established in the US. A recent 
systematic review of progestin and breast cancer risk published after the 1999 IARC review showed 
no overall association of progestin and breast cancer (Samson et al., 2016).  
       The emphasis on primary prevention in CVD and cancer health is essential for both the 
improvement of population health and the advancement of the epidemiologic field. This 
dissertation will provide information to fill gaps regarding POC use and specific chronic diseases 
among underrepresented groups in SC. This research will consider the benefits and risks associated 
with the use of POC for the primary prevention of stroke, CHD and breast cancer for an at-risk 
population. Findings may guide us to formulate more appropriate reproduction and sexual health 
strategic plans for high-risk populations. 
1.4 Specific Aims  
       SC Medicaid administrative enrollment and claims data (2000-13) from the Revenue and Fiscal 
Affairs Office will be used to investigate the association between POCs and breast cancer mortality, 
as well as stroke and CHD incidence, respectively. In 2010, the Medicaid Program provided 
comprehensive health care coverage to approximately 20% of SC residents (MLTSS, 2015); 
Medicaid is one of SC’s largest insurance providers.  
       The dataset includes information on women between the ages of 18 and 65 during a 13-year 
period and their demographic, medical and pharmacy claims. Medicaid is a comprehensive and rich 
source of critical information that will allow us to study the following three specific aims:  
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 Aim I: Describe and compare secular trends between COCs and POCs among low-
income populations by race/ ethnicity   
 Aim II:  
 
Evaluate the relationship between breast cancer mortality and POCs by race/ 
ethnicity 
 Aim III:  
 
Evaluate the relationship between heart disease and stroke incidence with  POCs 
by race/ ethnicity 
1.5 Summary  
       There is an increasing number of Americans suffering from contraindications of combined 
OCs. These contraindications are more prevalent in underserved populations (i.e. hypertension, 
diabetes, tobacco use, cancer) (Adler et al., 2002) and can be ignored when prescribing a 
contraceptive method due to miscommunication between health care providers and patients (Yee 
et al., 2011; , Isaacs et al., 2003;, Becker et al., 2003). Although the general population may not 
suffer from current prescription practices, many will have an increased risk of ADRs. OCs may 
lead to severe arterial hypertension in approximately 5% of women using combined preparations 
(Olatunji and Soladoye, 2010) and will elevate blood pressure in the majority of women (Woods, 
1988). This study may influence clinician prescription practices related to OC use for high-risk 
groups.  
       Identifying potential risk factors for the predominant causes of death for women will allow 
epidemiologists to initiate population-wide scale preventive interventions to reduce the burden of 
disease caused by certain background conditions. With the high burden of chronic diseases in the 
southeastern part of the US, SC is an ideal environment to study racial disparities associated with 
the type of contraceptive pill used, breast cancer, and CVD incidence and mortality. Focusing on 
preventive approaches to protect healthy individuals from developing CVD or cancer may be an 
effective means of reducing the burden and cost of implementing multiple methods of treatment. 
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       The ultimate goal of this epidemiologic research is to provide an extensive and rich source of 
support for women’s health that will positively impact societal health. This dissertation aims to 
inspire more research in POCs to determine which populations require this drug. More 
comprehensive oral contraception guidelines are necessary to offer a safe- and effective method of 
pregnancy prevention that does not contribute to chronic disease rates for high-risk groups.  These 
findings may provide a pertinent piece of the puzzle to contraception health.  
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CHAPTER II.  
LITERATURE REVIEW 
“An ounce of prevention is worth a pound of cure.” - Benjamin Franklin 
2.1 History of Oral Contraceptives  
Oral contraceptives (OCs) equipped women with an effective means to prevent unwanted 
pregnancies and establish autonomy in their relationships. Many people acknowledge the political 
and social obstacles that preceded the recent and revolutionary advancements in women’s health. 
Prior to the 1920s, the female reproductive cycle was considered sporadic and uncontrollable 
(Viterbo, 2004) and many depended on unreliable means of pregnancy prevention.  In addition to 
the general unawareness of women’s health, females were not allowed to make decisions or control 
their bodies. In fact, the United States (US) Comstock Act of 1873 criminalized contraceptives and 
the dissemination of birth control  information (Cox, 2015). This act was a barrier to understanding 
many components of family planning and women’s health.   
       Margaret Sanger challenged these laws by opening America’s first birth control clinic in 1916 
and educating women about pregnancy prevention (Cox, 2015). She is considered a pioneer in the 
American birth-control movement. Among the higher socioeconomic classes, the principal 
methods of contraception were the rhythm method, requiring abstinence from sexual intercourse 
during the “unsafe period,” or two weeks after menstruation (Viterbo, 2004) and the use of 
diaphragms, requiring internal fitting by doctors. Among lower classes, performing a self-
administered abortion was not uncommon; it was a less costly alternative to prevent additional 
children (Cox, 2015). 
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       Sanger advocated that a simpler and cheaper form of birth control would allow women to have 
greater access to birth control and therefore, more control of her own body. She believed: “No 
woman can call herself free until she can choose consciously whether she will or will not be a 
mother.” Mrs. Sanger allied herself with Drs. Gregory Pincus and John Rock, two scientists 
studying progestin, a synthetic progesterone, that could help reduce unwanted pregnancies. After 
discovering progesterone’s role in ovulation, these scientists developed an oral birth control agent 
that prevented ovulation in 90.0% of their cases (Viterbo, 2004;-Dhont, 2010). 
       Despite opposition, the pill was an important step in reshaping women’s attitudes towards sex. 
It helped erase the foundation supporting gender and sexual inequalities and gave women more 
power to enjoy a healthier view of sex (Montagu, 1968)  Feminist Sanger, with the assistance of 
Mrs. Katherine McCormick and scientists Pincus and Rock, made it possible for women of every 
socioeconomic class a more accessible form of birth control (Viterbo, 2004; -Dhont, 2010). 
2.1.1 Chemical compound   
       Since the body absorbs naturally occurring progesterone at very low levels, scientists searched 
for a chemical compound with potent progestogenic activity that would maximize its ovulatory 
prevention effects. Chemist Carl Djerassi discovered norethindrone, the first progestin that had the 
proper effect on the ovulatory system when given orally. Dr. Frank Colton developed 
norethynodrel, a close isomer of norethindrone and administered it to women in the first 
contraceptive trials. Scientists found it odd that a daily dose of 10 mg of norethynodrel resulted in 
no breakthrough bleeding but, when given norethindrone or a more purified version of 
norethynodrel, women typically experienced frequent bleeding (Dhont, 2010)  
       Later, scientists discovered that the original norethynodrel compound was contaminated with 
a synthetic estrogen, mestranol. This discovery encouraged the addition of 150 µg of the synthetic 
estrogen, mestranol, to the 10 mg progestin compound, norethynodrel, which resulted in the first 
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contraceptive pill, Enovid® (Dhont, 2010). In 1960, the Food and Drug Administration (FDA) 
allowed the use of Enovid® for contraception purposes to married women in addition to menstrual 
disorders. 
       This previous finding also sparked interest in estrogen-only oral preparations because of 
estrogen’s ability to suppress ovulation and control frequent bleeding (Viterbo, 2004; de Melo, 
2010). Like progesterone, the naturally occurring estrogen was poorly absorbed by the body, and a 
synthetic version had to be used (Dhont, 2010). Adverse estrogen-related effects on cardiovascular 
health terminated future plans of estrogen-only pills for population-wide use (de Melo, 2010). In 
fact, researchers have modified the original pill by reducing estrogen dosages (Dhont, 2010) in an 
attempt to provide a safer alternative to women choosing to use OCs as their primary means of 
birth control.  
       Despite progesterone’s critical role in the development of OCs, progesterone-only oral 
contraceptives (POCs) were ignored until the late 1960’s, as a response to the growing concern of 
estrogen’s side effects. It is important to examine the role of progesterone and estrogen in the 
female reproductive system in order for the reader to understand why these two hormones were 
targeted for pregnancy prevention therapies and the variations among current OCs. 
2.2 Female Reproductive System   
2.2.1. The Menstrual Cycle  
       The menstrual cycle is predominantly characterized by a sequence of follicular development, 
ovulation, and the luteal phase; altogether, the three phases typically last 28 days. The follicular 
phase may vary in length and is often responsible for the variability in the menstrual cycle. 
Ovulation is the midpoint of the cycle and separates the follicular and luteal phases; the latter is 
constant and occurs 14 days after ovulation. The luteal phase is responsible for the formation and 
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disintegration of the corpus luteum, which degenerates if a woman is not pregnant. This leads to a 
decline in progesterone levels, which stimulates menstruation (Bartke et al., 1998). 
       Estrogen and progesterone are responsible for the many changes in the cervix, endometrium, 
and vagina that occur during the menstrual cycle. These hormones are also responsible for feedback 
regulation of the follicle stimulating hormone (FSH) and the luteinizing hormone (LH) secretion 
by the anterior pituitary gland. The follicular and luteal phases are characterized by negative 
feedback on the anterior pituitary by estradiol and progesterone, respectively, whereas the mid-
cycle is characterized by positive feedback of estradiol on the anterior pituitary (Davis, 2015). 
       In each of the phases, the pulsatile activity of the hypothalamic-pituitary axis signals to the 
gonadotropin-releasing hormone (GnRH) to stimulate the anterior lobe of the pituitary and secrete 
gonadotropins: FSH and LH. Gonadotropins include several hormones that act on the gonads 
(ovaries or testes) to regulate normal growth, sexual development and reproductive function. In the 
mid-cycle, the secretion is mostly composed of LH to trigger ovulation and the corpus luteum 
(Davis, 2015; Wells et al., 2008). 
2.2.1. a. Follicular Phase  
       In conjunction with FSH and LH, a dominant follicle develops and stimulates high amounts of 
estradiol. FSH regulates aromatase enzymes that induce conversions of androgens to estrogens in 
the follicle. Estradiol will stop the menstrual flow from the previous cycle, change the environment 
of the cervix, and thicken the endometrial lining of the uterus. This follicle will continue to grow 
and synthesize estradiol, progesterone, and androgen until it ruptures and releases the oocyte. This 
phase is dominated by negative feedback effects of estradiol on the GnRH, which inhibit FSH and 
LH secretion by the anterior pituitary (Davis, 2015). 
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2.2.1. b. Mid-cycle  
       As a result of follicular cell proliferation and estradiol synthesis that occurs during the follicular 
phase, estradiol levels rise sharply during the mid-cycle. When a critical level of estradiol is reached 
(≤ 200 picograms per milliliter of plasma), an ovulatory surge of FSH and LH triggers ovulation of 
the mature oocyte. An ovulatory surge occurs due to estradiol’s positive feedback effect on the 
anterior pituitary approximately 14 days prior to menses. During ovulation, cervical mucus 
increases in quantity and becomes watery and more penetrable by sperm. Conception is most 
successful when sexual intercourse takes place two days prior to ovulation until the day of ovulation 
(Wells et al., 2008). Estradiol levels decrease soon after ovulation, but they will increase again 
during the luteal phase.  
       The progesterone component of oral contraceptives suppresses ovulation by changing the 
cervical mucus environment and making sperm hard to get through the cervix.  
2.1.1. c. Luteal Phase 
       During the luteal phase, the corpus luteum develops and begins synthesizing both estradiol and 
progesterone. Progesterone is the major hormonal secretion of the ovaries, and its high levels will 
increase the vascularity and the secretory activity of the endometrium. Another action of this 
hormone is to inhibit the secretion of FSH and LH through negative feedback loops to the anterior 
pituitary. Compared to the follicular phase, where estradiol causes the endometrial lining to 
proliferate, progesterone, in the luteal phase, prepares the endometrium to receive a fertilized ovum.  
       Increased progesterone levels during the luteal phase may lead to noticeable changes in the 
body, such as increased hypothalamic temperature set-point (increase basal body temperature) and 
thicker and more abundant cervical mucus. During this phase, the sperm can no longer fertilize the 
ovum. If fertilization has not yet occurred by then, the corpus luteum regresses and blood levels of 
the hormones decrease abruptly (Davis, 2015). 
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2.2.1. d. Ovaries and steroid sex hormones  
       Female gonads (ovaries) are involved in the production of steroid sex hormones, germ cells 
(ova), pregnancy, childbirth, and lactation. Steroid sex hormones are fundamental to normal 
development and function of the reproductive organs and differentiation of secondary sex 
characteristics. These hormones have both paracrine and endocrine functions: the ovarian steroid 
hormones paracrine function is to support the development of the ova within the ovaries and, its 
endocrine function, is to act on a variety of target tissues (uterus, breasts, and bones). Ovarian 
follicles synthesize female sex hormones through the functions of the theca (cholesterol desmolase) 
and granulosa cells (aromatase). In the biosynthetic pathway, these cells are stimulated by LH and 
FSH, respectively  (Bartke et al., 1998; Davis, 2015). 
       The three types of male and female sex hormones secreted are androgens, estrogens, and 
progestagens. Examples of each are testosterone, 17-β estradiol, and progesterone, respectively. 
Ovaries only secrete the female sex steroid hormones: progesterone and estrogen (Bartke et al., 
1998). These sex steroid hormones are a vital part of hormonal contraceptive methods used in the 
US.  
2.3 Contraception methods 
       Nowadays, there is a plethora of pharmacologic and non-pharmacologic contraception 
methods used to reduce the risk of unintended pregnancies, including diaphragms, condoms, 
spermicides, intrauterine devices, and hormonal contraceptions. These vary in effectiveness, 
popularity of use, and mechanism of prevention. Due to the widespread use of hormonal 
contraception’s, such as oral contraception pills, transdermal contraceptives, contraceptive vaginal 
rings, long-acting injectable and implantable contraceptives (Wells et al., 2008), there has been a 
lot of interest in the field of combined estrogen- and progestin- contraceptives. In recent years, this 
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interest has slightly dwindled despite the constant and relatively high rates of birth control use 
among women (OWH, 2014).  
       Healthy People (HP) was created to improve the health and quality of life of all Americans and 
provides 10-year national benchmark for a wide-variety of health issues. Reproductive and sexual 
health is one of the leading health indicators (LHI) of HP 2020 and includes unintended pregnancy 
prevention. As part of the LHI, HP 2020 aims to increase the proportion of females at risk of 
unintended pregnancies or their partners who use contraception at the most recent sexual 
intercourse. This requires targeting high-risk populations: females ages 15-44, non-white Hispanic 
women, and those whose family income are below the poverty threshold. The goal is to increase 
the amount of females from 83.3% to 91.6% (HP 2020, 2015). If this goal is reached, health care 
providers must consider unique considerations (e.g. family history, genetic predisposition, lifestyle 
factors) faced by women while prescribing the appropriate contraception method.  
       Young women typically consider OC pills as their preferred method of contraception (NCHS, 
2014) and most women using OCs use combined oral contraceptive (COC) pills (Marchbanks et 
al., 2002; Hall, et al., 2012). Severe symptoms of COCs may be rare but include blurred vision, 
flashing lights, numbness and/or weakness (may be a sign of stroke), hypertension or vascular 
problems at many sites; breast mass (may be a symptom of breast cancer); and chest pain or 
shortness of breath (may be a sign of pulmonary embolism, heart disease or myocardial infarction 
(MI)) (Wells et al., 2008). These risks are much lower in POC formulations. 
       There is a paucity of literature regarding POCs and thus will be the primary focus of my 
dissertation.  
2.3.1 Progesterone-only contraception 
       Progestin-only contraceptives are available in many forms: injections, implants, oral 
preparations, hormone-releasing intrauterine devices and emergency contraceptives (IARC, 1999). 
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This dissertation will focus on oral preparations, or OC pills. It may be hard to distinguish between 
POC and preparations that contain estrogen and progestin, or combined oral contraceptives (COC) 
in the current literature because many respondents may not make the appropriate distinctions 
between the type of OC pill used when answering about their (any) use of the pill.  
       In the US, POCs, or the “mini pill,” are all composed of 0.35 mg norethindrone, a progesterone 
of the norethisterone family. Brands and generics of the pill include Camila, Errin, Micronor, 
Jolivette, Nora-be and Nor-QD (Marchbanks et al., 2002). Compared to COC users, women using 
POCs have a much more limited variety of pills to choose from. The current POCs available tend 
to have low progestin activity, and range from none-to-low estrogen and androgen activity. Women 
using these compositions of pills experience a high percentage of spotting and breakthrough 
bleeding in the beginning of pill use; however, these effects attenuate over time (Marchbanks et 
al., 2002). 
       Women who choose POCs must take into account certain considerations that may be less 
important for women with COCs. For example, doctors recommend that women using POCs adhere 
more strictly to current guidelines (table 2.1) regarding daily intake (within a three hour window) 
to maximize the pills effectiveness because the effect on the cervical mucus lessens 20-22 hours 
after administration (IARC, 1999). Table 2.1 shows the guidelines for OC use according to the US 
Medical Eligibility Criteria for Contraceptive Use (MEC) by OC type (COC or POC) (Curtis, 2010; 
CDC, 2013). The pregnancy rate among COC users and POC users is the same among perfect users, 
but in typical use (table 2.2), the rate is slightly higher among POC users (0.3-5 per 100 women per 
year of use) (IARC, 1999).  
       Progestin is useful in controlling uterine bleeding and menstrual disturbances, reducing pain 
related to dysmenorrhea or menorrhagia and premenstrual syndrome, treating endometriosis, and 
postponing menstruation. In some women, POCs suppression of gonadotropin secretion and 
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ovulation can cause them to no longer menstruate.  Researchers and health care providers believe 
POCs are more suitable for women over the age of 35, heavy smokers, those with a history of 
thromboembolism or hypertension, or in women who estrogens are typically not advised (e.g. 
diabetic women) (Wells et al., 2008). Scientists find that the small doses of progestin in POCs lead 
to minimal disruption of lipid or carbohydrate metabolism (Dhont, 2010;-Wells et al., 
2008;,Marchbanks et al., 2002). 
2.3.2 Pharmacoepidemiology 
       Pharmacoepidemiology is defined as the study of the utilization and effects of drugs in large 
numbers of people (Strom et al., 2007). OC’s are recommended for both preventing unintended 
pregnancies and for off-label uses; in the US, the use of approved drugs for non-approved 
indications is not prohibited (IARC, 1999). OC’s can alleviate menstrual cramps and ovulatory 
pain; moderate blood flow and acne; reduce the risk of ovarian and endometrial cancer; and also 
reduce the risk of ovarian cysts, ectopic pregnancies, and pelvic inflammatory disease (Wells et al., 
2008) The pill has been used by approximately 200 million women (Gogos et al., 2014) because 
of its ability to protect against pregnancy and to reduce menstrual cramps, acne, certain cancers and 
other female complications in a convenient way. 
       Due to the increased prevalence of medication use among women, it is becoming imperative 
to analyze the effects of drugs that are currently in the market. The passage of the Patient Protection 
and Affordable Care Act (ACA) may continue to play an increasingly vital role in the percentage 
of women using OC’s in the future due to less health care barriers. Thus far, ACA has increased 
access to contraception methods by requiring health care among all American citizens, which 
includes women’s preventive services without cost-sharing. Congress anticipates that more 
Americans will continue to sign up for the ACA to avoid penalty and thus use health care services 
more frequently. This highlights the time-sensitive nature of this study. Pharmacovigilance must 
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be practiced routinely to understand, detect, assess, and prevent adverse effects or other OC-related 
problems (Strom et al., 2007). 
       Numerous studies have suggested that COCs may lead to certain adverse drug reactions 
(ADRs). Known ADRs of COCs are abdominal pain, nausea, vomiting, headaches, breast 
tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, 
pulmonary embolus, and cerebral thrombosis (Wells et al., 2008;, Micromedex, 2015; ,FSRH, 
2011) Currently, the carcinogenicity of COC use is only confirmed in hepatocellular carcinoma 
with long-term use of COCs (Micromedex, 2015).  Despite these risks, COCs are prescribed in the 
majority of women who use OCs. It is unclear how many women are counseled about the mini-pill 
when choosing the right OC for them. The POC may be another alternative, with similar efficacy, 
that has been overlooked due to bleeding disturbances in clinical trials in the past (Kovacs, 1996). 
POCs have thus far been associated with less ADRs and contraindications than COCs. It may be 
more suitable to consider POCs in more cases during contraceptive consultations.  
       We will now assess the complications related to non-bioidentical or synthetic versions of 
estrogen and progesterone, which play an important role in the make-up or composition of the 
different pills.  
2.3.2. a. Estrogen and Progesterone compounds  
       Naturally-occurring estrogen and progesterone chemical actions vary from their synthetic 
versions in physiology and clinical outcomes (Holtorf, 2009). Due to issues in absorption of 
bioidentical hormones (Dhont, 2010), birth control pills use the non-bioidentical versions, which 
are associated with increased risks of breast cancer and cardiovascular disease. We must assess 
effects of synthetic hormones on women’s overall health if we want to continue prescribing these 
hormones to women in the future.  
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2.3.2. a. i. Synthetic Estrogen  
       In the US, ethinyl estradiol (EE) and mestranol are the two forms of synthetic estrogens 
typically used (Dhont, 2010;-Wells et al., 2008). Mestranol converts into EE in the liver (Wells et 
al., 2008) and contains 67.0% of its estrogenic activity. Researchers found that estrogen and EE 
can stimulate the synthesis of several clotting factors and hepatic proteins and through observations 
of pregnant women, identified estrogen’s link with thromboembolism(Dhont, 2010). A progressive 
reduction from 50 to 15 µg of EE was associated with less side effects, such as breast tenderness, 
nausea, and bloating, but did not eliminate prothrombotic effects (Dhont, 2010). 
       In addition to the aforementioned complications, many estrogen-related side effects of COCs 
include, fluid retention, hypertension, leg pains, cramps, reduced sex drive, depression, migraine/ 
headaches, visual disturbances, decreased tolerance to contact lenses, increased skin pigmentation 
and changes in glucose tolerance (diabetic patients) (Wells et al., 2008)  Uncommon, but estrogens 
increase in blood coagulation can sometimes lead to venous thromboembolism (VTE), cerebral 
hemorrhage, embolism, stroke, and MI. Women using COC’s who are older than 35 and who smoke 
are at much higher risk for MI.  
       Due to the number of complications that can result from using this drug, official guideline 
recommendations that are based on good and consistent scientific evidence recommend COCs with 
35 mcg or less of EE and less than 0.5 mg of norethindrone to women who are younger than 35 
years until the ages of 50-55 if they are healthy, after weighing the risks and benefits (ACOG, 
2006). Women with a history of benign breast disease or a positive family history of breast cancer 
should not be considered contraindicated for COC use. Women with a history of unexplained VTE, 
smoking, breastfeeding, hypertension, end-organ vascular disease, focal neurologic signs, and other 
certain predispositions should not use COCs. Furthermore, women are highly recommended to 
discontinue estrogen containing OCs prior to any significant surgery (Wells et al., 2008). Whether 
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this recommendation, or other important considerations of the pill are articulated to women is 
undocumented and unknown. Many of these precautions do not exist for women who use POCs. In 
fact, based on consensus and expert opinion, POCs may be appropriate for women with CHD, heart 
failure, and cerebrovascular disease while COCs are contraindicated in these women (ACOG, 
2006).  
       There are many more options of COCs to satisfy the user: monophasic, biphasic, triphasic, and 
extended-cycle pills. The first three types require women to take estrogen and progestin for 21 days 
followed by 7 days of placebo, while the extended-cycle pills increase the number of hormone-
containing pills from 21 to 84 days, followed by a 7-day placebo phase. A monophasic combination 
tablet has a single synthetic estrogen and progesterone that mimics typical menstruation due to a 
decrease in progesterone levels. Many women might prefer this method because “breakthrough 
bleeding” can be psychologically reassuring of non-pregnancy. The biphasic and triphasic 
combinations have varying hormone levels of estrogen and progesterone as the cycle continues and 
tablets must be taken in a particular order throughout the month. The extended method reduces the 
yearly amount of menstrual cycles per year to only 4 (Wells et al., 2008; FSRH, 2011). 
       All pills, despite phasic combination, should be taken at the same time daily and lose 
effectiveness if taken late (more than 12 hours) and in conjunction with other drugs that influence 
estrogen and progesterone metabolism or certain antibiotics that affect the flora (Wells et al. 2008; 
FSRH 2011).  
2.2.2. a. i.1. Progestin activity in combined pills  
       Despite norethindrone being the only progestin used in POC pills, desogestrel, norgestimate, 
levonorgestrel, dienogest, and other progestin compounds have been used in COCs, commonly 
referred to as “the pill.” The progestin component of COCs is essential for contraceptive efficacy; 
it suppresses LH secretion, thereby inhibiting gonadotropin secretion and preventing ovulation 
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(Barbieri et al., 2009). The UK committee of safety of medicines found that COCs containing 
desogestrel or gestodene were associated with a two-fold increase in thromboembolism compared 
to COCs containing androgenic progesterone’s, such as levonorgestrel or norethisterone (Wells et 
al., 2008) The progestin activity in COCs is outside the scope of this work but can provide insight 
into the role of estrogens when combined with progestin.  
2.2.2. a. ii. Synthetic Progesterone or Progestin 
       Norethindrone is the primary form of synthetic progesterone and alone makes up the “mini-
pill.” Progestins have many chemical structures: estranes, gonanes, and others. Gonanes, the 
norgestrel family of progestins, include: desogestrel, gestodene, norgestimate, and etonegestrel. 
The estrane family of progestin’s, including norethindrone, norethynodrel, norethindrone acetate, 
and norgestimate among others, are converted to norethindrone when metabolized. Gonanes exhibit 
a higher progestational effect per unit weight than estranes (Marchbanks et al., 2002; Barbieri et 
al., 2009)  
       The synthetic form of progesterone closely resemble testosterone; may bind to progesterone 
receptors or activate other steroid receptors; and can metabolize as estrogenic substances (Dhont, 
2010). Thus, progestin can demonstrate estrogenic, anti-estrogenic, and androgenic properties 
(Marchbanks et al., 2002).  
       The current progestin dose used in POCs are lower than in COCs to minimize androgenic 
ADRs (de Melo, 2010). In the limited studies about POCs, low androgenic progesterone’s reduced 
the increased risk of CVD seen in typical COCs and could reduce blood pressure (Wilson et al., 
1984;, Staffa et al., 1992). The major side effect of POCs are an increased occurrence of bleeding 
during the first cycle compared to COCs (excluding triphasic therapies) (Wells et al., 2008; Barbieri 
et al., 2009). There is also a weak risk of an ectopic pregnancy in patients who become pregnant 
while on the pill due to decreased tubal motility (Wells et al., 2008). All other observed side-effects 
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of COCs are less prominent or nonexistent in POC users, such as headache, nausea, depression, 
acne, fluid retention, and breast discomfort. Furthermore, no significant increased risk of CVD and 
breast cancer has been demonstrated with POCs and researchers speculate that POCs may have 
fewer long-term consequences on health, including weight gain and increased appetite (FSRH, 
2009). 
       More studies need to examine other contraindications for POCs and examine the types of 
progestin structures in OC formulations. Currently, POCs have fewer contraindications than COCs 
and are a much safer option for women choosing an OC therapy.  
2.3.3 Choice of Oral Contraceptives 
       Studies assessing women’s knowledge of OCs are outdated (Koch et al., 1993; Smith et al., 
1995; Jones, 1999). With the new HP 2020 goals focusing on increasing contraception use to almost 
100% (HP 2020, 2015), researchers should renew their focus on understanding the factors that 
promote and discourage women’s choice of OCs. It is also important to examine the efficacy of 
healthcare provider’s communication of contraceptive contraindications and alternative choices 
with patients.  
       Studies need to assess awareness of alternative OC types (mono-, bi-, tri-, or extended COCs 
or POCs) among past, current and future pill users and health care provider’s ability to consider 
family history, genetic predisposition, and other important lifestyle factors with newly imposed 
time constraints when prescribing OCs.  
       Like many other medications, OC prescriptions requires special consideration of the 
individual. Contraindications of OCs consider age, behavior, family history, and coexisting 
conditions (Wells et al., 2008;, FSRH, 2009).  A previous study showed that health care providers 
often do not provide the necessary provisions and advice about the best OC to use to women 
suffering from Type 1 or Type 2 Diabetes Mellitus (Shawe et al., 2011).   There is limited 
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information about other chronic diseases and OC counseling. Currently, we cannot compare the 
existence of a parallel relationship between diabetes and other chronic diseases and inadequate 
counseling of OCs. The growing prevalence of chronic diseases and their risk factors are putting 
high demands on clinicians to prescribe OCs with regards to patient-specific characteristics in order 
to increase OC safety among high-risk groups and decrease long-term ADRs.  
2.4 South Carolina: Women’s Health   
2.4.1 Demographic Characteristics  
       In 2012, more than half of the 4.72 million people living in SC were females. The racial/ethnic 
distribution of the female residents were primarily non-Hispanic white (64.3%) and black (29.1%) 
women. Combined, American Indian, Asian/Pacific Islander, and Hispanics made up less than 8% 
of the composition. Economically, approximately 20% of females in SC are below the poverty 
level. The highest rates of poverty disproportionately affect minority populations: Hispanics 
(33.5%), Blacks (31.4%), American Indian (26.3%), and Asian/ Pacific Islander (14.0%). White, 
non-Hispanic females (13.7%) have the lowest percentage of women below the poverty line.  
       Among those women 18 years of age and above, 20% were smokers, 40% were hypertensive, 
and 35% had high cholesterol.  Of those who smoked, 23.6% were white, non-Hispanic, 14.1% 
black, non-Hispanic, and 13.4% Hispanic. Of those who were hypertensive, 31.4% were white and 
more than half were black. Of those with high cholesterol, 34.9% were white, and 34.7% were 
black (DHHS, 2015). SC is an important region to carefully consider contraindications during OC 
prescription. Due to heightened prevalence of chronic disease risk factors and OC contraindications 
in this population, women may be more at risk to suffer ADRs related to COCs.   
       Women in SC typically range between 15-44 years of age (6.2% 15-19 and 32.1% 20-44) 
(DHHS, 2015). About 40% of teenage girls living in SC are sexually active and the majority have 
or will consider using an OC pill (DHHS, 2015). Among women participating in sexual intercourse 
 29 
 
in the US, more than 99% have used at least one contraception method (DHHS, 2010). From 2011-
2013, approximately three-fifths of women 15-44 were using a type of contraception and COC pills 
were the most common form (CDC, 2013).  
       Despite higher use of contraceptives among women aged 24-34 (67.4%), almost half of women 
ages 15-24 (47.4%) and the majority of women 35-44 (70.0%) also used contraceptives. Pill use 
was higher among younger women (15-24 years of age), with almost 1 in 4 using the pill compared 
to older women (35-44 years) with about 1 in 12 women using the pill. Non-Hispanic white women 
(65.3%) were the most likely to use contraception’s compared to Hispanic women and non-
Hispanic black women (57.3 vs. 57.9 percent, respectively). The percentage of women aged 15-44 
who used the pill is significantly higher than condom, and long-acting reversible contraceptives use 
(DHHS, 2015).  
       The National Survey of Family Growth (NSFG), a nationally representative survey conducted 
by the National Center for Health Statistics, collected information on use of contraception from 
2006-2010. Among the 88% of women who reported having used a contraceptive (n=10,779), 73% 
reported having used an OC. The majority of OC users identified using a COC. Only 2.8% (n=57) 
of women who were currently using OCs (n=2032) identified a POC as their current method (Hall, 
et al., 2012).  
       The proportion of women aged 15-44 in the US who used the pill were almost twice as high 
among non-Hispanic white women as compared to non-Hispanic black and Hispanic women. The 
percentage of women ages 15-44 using a contraceptive method in 2011 to 2013 is similar to 2006-
2010 (62.0 vs. 62.2%) (NCHS, 2014)  Additionally, the percentage of women who used the birth 
control pill the last time they had sex ranged from 12.3% in Oklahoma to 35.7% in Maine. In SC, 
black female students in grades 9-12 were significantly more likely to have sexual intercourse than 
their white student counterparts (52.8% vs. 40.2%). Insufficient data examines whether black 
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females used a condom, birth control pills, an IUD, or a shot (eg. Depo-Provera, patch, or birth 
control ring) before or during the last sexual intercourse among students who were sexually active 
but among whites, the majority of the students used a condom (51.8%) and/ or birth control pills 
(25.3%). Including male responses, both black and white students in SC high schools used birth 
control pills 17.0- 18.4% of times prior to the last time they had sexual intercourse. There was no 
significant difference between race and birth control pill use (CDC, 2013). 
       Due to the high use of OCs noted in women ages 15-44 and high prevalence of chronic disease 
risk factors and COC contraindications, the low percentage of women reporting POC use is of 
public health concern.  
2.4.2 Health disparities  
 
       The CDC defines health disparities as the ‘differences in health outcomes between groups 
that reflect social inequalities’(Frieden, 2011). Poorer health status can manifest as a result of 
marked differences in social economic status and access to care among racial/ ethnic groups. 
Other characteristics linked to poorer health outcomes include gender or gender identity, 
geographic location, religion, age, mental health, and disability.  
       Our SC Medicaid cohort of women primarily suffer discrimination by gender (female), 
race/ethnicity (black), and geographic location (Southeast US). To increase equality in health care 
among different groups, we must increase the information about excluded groups in science and 
adhere to quality measures that focus on action plans that aim to reduce disparities in health care. 
The Department of Health and Human Services (HHS) has created a few measures to transform 
health care and to achieve HP 2020’s goal of assessing health disparities for sub-populations to 
achieve health equity for all groups (DHHS, 2011). 
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2.4.2. a. Medicaid  
       In accordance with the HHS Disparities Action Plan, I will use Medicaid data to assess racial 
and ethnic disparities in the state of SC. The HHS plan recommends increasing using administrative 
data as a surveillance system to monitor trends in health and quality of care measures (DHHS, 
2011). Medicaid is an ideal source because it is representative of underrepresented populations and 
provides most medical expenses for low-income women and children. 
       Since 2014, a massive expansion of Medicaid eligibility for low-income Americans promised 
an increase in Medicaid recipients and, with respect to women, the ACA will increase coverage of 
preventive services for FDA-approved contraceptive services and supplies as prescribed. SC has 
opted out of Medicaid expansion programs; nevertheless, it will see a 16% increase in Medicaid 
enrollment and possibly in OC use after the full implementation of the ACA (Galewitz, 2015).  
2.4.2. b. Race, gender, and geographic location  
       SC is one of ten states located in the southeastern region of the US. It is uniquely positioned to 
study health disparities because it has a higher percentage (%) of black or African Americans 
(27.9), female persons (51.3) and persons below poverty level (18.1) than the rest of the US (13.2, 
50.8, and 15.4, respectively) (US Census Bureau, 2015). Thus, an analysis of SC can provide 
valuable insight into gaps in health care outcomes between certain populations. In accordance with 
HP 2020, we hope that the studies undertaken in this dissertation will help achieve health equity, 
eliminate disparities, and improve the health of all underserved populations.  
2.5 Chronic Diseases  
       In the US and SC, the burden of chronic diseases (stroke, heart disease, cancer, diabetes, 
arthritis) and their associated risk factors are the leading causes of morbidity and mortality for 
women (CDC, 2008). It is estimated that one in three women will die of heart disease, one in six 
of stroke, and one in twenty-five of breast carcinoma (Jordan, 2001). In 2010, the Centers for 
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Disease Control and Prevention (CDC) placed SC among the two highest quintiles for the following 
age-adjusted death rates: 1) all-cause (700.8-813.8), 2) heart disease (143.3-165.1), 3) all cancer 
(150.0-157.6), 4) stroke (43.9-80.6), and 5) diabetes-related illnesses (62.9-71.7) among females 
of all ages (per 100,000).  
       CVD was responsible for 30 percent of all deaths in 2008 and despite a noticeable decline in 
mortality rates since 1999, SC mortality rates remain higher than the national rate. In assessing 
relevant risk factors for chronic disease occurrence, SC high school students and adults are at a 
higher risk compared with the US in 90% of the risk factors (Khosrow, 2010) With the poor 
distribution of health status in the state, health care providers should prescribe more take this into 
account when considering the best OC formulation for women.  
       In SC, the distribution of major contraindications, including smoking status, age, hypertension, 
cholesterol diabetes, for COC prescriptions are relatively high. More than 20% of women in SC 
currently smoke, do not partake in leisure time physical activity (LTPA), are overweight, obese, 
hypertensive, have high cholesterol and arthritis. Despite a lower prevalence of diabetes (12.4%) 
in SC compared to other risk factors, there is a high prevalence of diabetes among blacks (19.4%) 
(DHHS, 2015). Therefore, there is a high prevalence of women in SC who should not be given 
COCs as a preferred contraceptive method.  
       HP 2020 aims to decrease overall morbidity and mortality related to breast cancer and CVDs, 
particularly CHD and stroke. Cardiovascular health can be improved drastically through prevention 
and treatment of risk factors (HP 2020, 2015). CHD and stroke are among the leading causes of 
death in females but also, one of the most preventable diseases. The leading modifiable risk factors 
for these CVDs are high blood pressure, high cholesterol, smoking, diabetes, physical inactivity, 
and weight. The national target for CHD and stroke rates are 100.8 and 33.8 per 100,000, 
respectively (OWH, 2014). 
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       HP 2020 objectives include reducing the incidence of high blood pressure and obesity (age 20 
and over) to 26.9 and 30.6 per 100,000 respectively; and increasing health insurance coverage for 
people 18-64 years old to 100.0%. The realization of these goals will reduce morbidity and 
mortality related to not only high blood pressure and obesity but to breast cancer and CVDs. To 
further control breast cancer, HP 2020 also wants to reduce the breast cancer mortality rate to 20.6 
per 100,000. These goals are harder to reach among black populations because they tend to have 
higher mortality related to CVDs and breast cancer compared to whites. Non-Hispanic whites 
(21.2) have lower rates of death from breast cancer than non-Hispanic blacks (26.9).  The same 
pattern is seen in stroke (41.7 vs 55.7) and CHD (77.6 vs. 98.5) mortality (per 100,000 rates age-
adjusted) (OWH, 2014).  
       In SC, a large percentage of women have high blood pressure, are obese, smoke, eat less than 
five fruits and vegetables a day, and have sedentary lifestyles (OWH, 2014). In 2011-2012, SC 
ranked among the highest percentage of women 18+ with a diagnosis of high blood pressure (32.1-
38%) and women aged 20+ who are obese.  
       We have the ability to analyze the SC Medicaid population, which is a high-risk group for 
chronic disease incidence. Studying this population may help us find a successful therapeutic 
intervention to decrease the risk of these disease. This study could have a large impact on women’s 
health.  
2.5.1 Breast Cancer  
2.5.1. a. i. Hormone Role  
       Breast cancer occurs from uncontrolled cell growth in the breast tissue (Adami, et al., 2008) It 
is the most common form of cancer in women and the second most common cause of cancer death 
in all women (Lopez-De et al., 2010). A few of the strongest risk factors for breast cancer are 
gender, age, and race; studies have shown that there may be a strong link between race and breast 
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cancer severity (Boyle, 2012;  Carey et al. 2006).  Women with high-risk for breast cancer, should 
perform self-examinations and routinely undergo mammography screenings. Breast cancer can be 
characterized based on TNM staging—T refers to the size of the primary tumor, N refers to the 
lymph node involvement, and M stands for the presence or absence of metastasis. These breast 
cancers are divided into stage 0 in situ, stage I-II local, and stage IV distant (Adami et al., 2008). 
The criteria used to determine stage and grade of breast cancer has been explained previously 
(AJCC Cancer Staging Manual, 2010).  Due to the complicated nature of the disease, it is important 
to reduce a woman’s risk to breast cancer by reducing her exposure to possible carcinogens.  
       Studies of POC use and breast cancer ranging from 1968 to 1987 were inconclusive (IARC, 
1999). Following studies of the relative risk of breast cancer among women with any versus no use 
of POCs showed no significant increased risk. “The Pill” is the “precursor of hormone 
regulators”(Montagu, 1968), and can interact with many hormone pathways that play a role in 
breast cancer. Hormone receptors play an important role in breast cancer prognosis.  
       Breast cancers with hormone receptor-positive (HR+) estrogen receptors (ERs) and 
progesterone receptors (PRs) often have a better prognosis. The expression of these receptors are 
often key to treatment and researchers suggest a potential significance of progestin’s in the 
treatment of breast cancer (Lin et al., 2001). ER- and PR-negative breast cancers are hormone-
independent breast cancers that account for almost half of all breast cancers and are associated with 
poorer diagnosis (Lin et al., 2001). These are much more common among African American 
populations (Carey et al., 2006).  To improve disease prognosis, scientists have recommended 
possibly reactivating the PR gene expression in hormone-independent breast cancers to promote 
progesterone ability to inhibit tumor growth and metastasis (Lin et al., 2001). 
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2.5.1. a. ii.  Demographics/ Medicaid  
       Approximately 1 in 4 women ages 15-24 are using the pill. The National Institutes of Health 
(NIH) estimated the lifetime risk based on current rates: 1 in 8 women born today will be diagnosed 
with breast cancer (Lopez-De et al., 2010). In 2010, 3,676 (0.39%) of SC Medicaid recipients paid 
claims associated with a primary diagnosis of breast cancer. The medical expenditures for this 
population ($58,399,037) accounted for 1.13 percent of SC Medicaid expenditures (Lopez-De et 
al., 2010). That year, the majority of the Medicaid population consisted mostly of women ages 19-
64, living in urban areas.  Among those with breast cancer, there were more women (n=3,675) than 
men (n=1); blacks (n=1,858) than white (n=1,474) and Hispanics (n=56) and urban (n=2,323) than 
rural (n=1,334). The age distribution ranged from 18 and under (n=6), 19-64 (n=2,367), to 65+ 
(n=1,303).  
       Currently, breast and cervical screening rates in SC are below the 50th National Medicaid 
Percentile Benchmark (DHEC, 2015). Compliance with screening guidelines is an important health 
care priority to reduce late-stage breast cancer, mortality, and associated health care expenditures.  
2.5.2 Cardiovascular disease (Heart Disease and Stroke) 
       CVDs are diseases of the heart and blood vessels (Labarthe, 2011). CHD is the major 
component of cardiovascular morbidity and mortality and refers to atherosclerosis of the arteries 
supplying the muscles of the heart.  The southeastern part of the US, is often referred to as the 
“Stroke Belt,” due to its high rates of hypertension-related CVD. In 2010, SC had the highest age-
adjusted stroke mortality rate in the US. In addition to the geographic disparities, the prevalence of 
these diseases are much higher among Blacks (Cruz-Flores et al., 2011; Cooper et al., 2000)  
       CVD is currently the number one cause of death in men and women and it is estimated that 
more than 90 million Americans are living with some sort of CVD (Cruz-Flores et al., 2011; Lopez-
De et al., 2010).  Hypertension is currently the most expensive component of CVDs and is projected 
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to increase from 130 billion dollars to more than 200 billion dollars in 2030 (Lopez-De et al., 2010) 
OCs have been found to increase the risk of hypertension among current users and the duration of 
pill use has increased this risk (Chasan-Taber et al., 1996). CVDs have many opportunities for 
prevention and is thus a ripe area for public health interventions.  
2.5.2. a. i. Hormone 
       Estrogen has many cardiovascular effects, including modulating vascular function, 
metabolism, insulin sensitivity, cardiac myocyte, stem cell survival, hypertrophy development, and 
inflammatory responses (Murphy 2011). Estrogen has been shown to improve many of the 
cardiovascular functions and can reduce atherosclerosis. Many scientists have identified estrogen 
as “cardio protective” (Gouva et al., 2004). Thus, it can be puzzling to hear that estrogen-related 
components of hormone replacement therapy or OCs are increasing negative health outcomes.  
       The Women’s Health Initiative (WHI) showed that estrogen may have detrimental effect on 
women’s health. In the study, women had an increased chance of blood clots and other health 
complications. Many OC pills have higher doses of estrogen than hormone replacement therapy 
(HRT) formulations, which caused scientists to question the safety of OCs. Women using COCs 
are at a higher risk for stroke than women of similar age groups who are not using estrogen-
containing OCs because estrogen induces embolism. This risk may persist after OC is no longer 
being used but declines after a woman is no longer a current user. Furthermore, young women who 
consider themselves healthy may not know that they are predisposed to strokes and take COCs. 
After an injury, using COCs can lead to thrombosis or other complications among women with 
subclinical disease. Women who have a mutation in the prothrombin gene have a twenty-fold 
increased risk of stroke. Despite guidelines allowing women with lupus to use COCs, women with 
a lupus anticoagulant have a three-fold increased risk for arterial and venous thrombosis (Bier, 
2011).  
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       A possible explanation for the contradictory findings (“cardio protective vs. stroke-inducing) 
are the role of endogenous vs exogenous reproductive hormones. It is possible that endogenous 
estrogen may play an important role in reducing cardiovascular complications but exogenous 
estrogens bind to certain estrogen receptors that do not confer the same protective capabilities. It is 
not well understood how estrogen regulates cardiovascular function in pre- or post-menopausal 
women but scientists believe that the ER mediates the relationship between estrogen and 
cardiovascular health. Estrogen can increase, decrease, or have no effect on transcription depending 
on the receptor it binds to and thus far, estrogen has been shown to signal by at least three different 
receptors (Murphy, 2011; Trussell, et al., 2009).  Estrogen pathways are complex and still being 
studied in further detail (Davis, 2015).  
2.5.2. a. ii. Pro-inflammatory Indices  
       Estrogen containing oral contraceptives can have a negative effect on females due to their pro-
inflammatory properties.  The estrogen component can lead to significant increased on high-
sensitive C-reactive proteins, which is an important marker of inflammation. C-reactive proteins 
can be an accurate method of identifying groups that are at high-risk for cardiovascular disease and 
cancer. Researchers found the effects of exogenous estrogen alarming: half of women who would 
otherwise be considered healthy women in the population exceeded recommend C-reactive protein 
levels (> 3 mg/l) after using oral contraceptives that included estrogen (Rietzschel et al. 2007; Kluft 
et al. 2002).   
2.5.2. a. iii. Medicaid Demographics 
       In 2010, 22,408 (2.37%) of SC Medicaid recipients paid claims associated with a primary 
diagnosis of CVD. The medical expenditures for this population ($359,582,929) accounted for 7.0 
percent of SC Medicaid expenditures (Lopez-De et al., 2010). The 2010 SC Fiscal Year for the SC 
Medicaid population includes black (n=10,111), white (n=10,299), Hispanic (n=136), and other 
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(n=1,862) races/ ethnicities of men (n=8,125) and women (n=14,283). The majority of Medicaid 
recipients resided in urban (n=13,025) areas and were ages 19-64 (n=11,149) (Lopez-De et al, 
2010).  
2.5.2. a. iv. Coronary Heart Disease  
       Ischemic heart disease occurs when an obstruction to the coronary artery results in a lack of 
oxygen to the myocardium, or the muscles supplying the heart (Labarthe, 2011)  The classic 
symptoms (sweating, faintness, and pressing pain) of heart disease may not be present among 
women experiencing myocardial ischemia. This causes increased harm to women because it is more 
difficult to diagnose in this population.  
       Medicaid records use International Classification of Diseases (ICD) codes for CHD or 
ischemic heart disease. Ischemic heart disease or CHD includes angina pectoris, acute MI, 
subsequent MI, certain complications following acute MI, other acute ischemic heart disease and 
chronic ischemic heart disease (Labarthe, 2011). In 2011, 9,000,000 people lived with angina 
pectoris (chronic chest pain),5,700,000 had heart failure and 16,300,000 had CHD nationwide 
(Lopez-De et al., 2010). Thus, it is important to understand the disease and possible areas for 
prevention.  
       There are common features of coronary events (Figure 2.1). This figure depicts the clinical and 
biological progression of heart disease in four phases (Labarthe, 2011) —  
1) Phase I: Background  
Atherogenesis leads to atherosclerotic lesions in the coronary arteries  
 Formation of abnormal fatty deposit in the arteries (Merriam-Webster, 2015) 
2) Phase II: Initial/ Potential Factors  
Presence of one or more potential factors may disrupt advanced atherosclerotic lesion or 
plaque at the surface or by fissuring deeper levels of the lesion  
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3) Phase III: Acute Events  
An acute event, such as a thrombus (large occlusive clot) may form and produce acute 
symptoms, such as unstable angina; heart attack; MI; or sudden death.  
4) Phase IV: Medium to late development  
The last phase characterizes short-or long-term outcomes from the first three phases.   
 Background conditions may lead to silent infarction/ asymptomatic disease  
 Initial factors may lead to spontaneous resolution or plaque enlargement as well as 
silent infarction/ asymptomatic disease  
 Acute events may lead to spontaneous recovery, short-term fatalities, late 
recurrence or late coronary death  
       From an epidemiologic perspective, it is important to understand these phases to reduce the 
role of extrinsic factors and intrinsic factors on disease occurrence/ progression. For example, a 
young women who does not engage in physical activity and has a family history of MI might not 
be an ideal candidate for combined oral contraceptives. Overlooking her current and past behavior 
and family history due to age might be catastrophic after the incubation period necessary for 
background conditions to progress into more advanced phases.  
2.5.2. a. v. Stroke  
       In the US, stroke death rate and prevalence are about 1/4th to 1/3rd as common as CHD. Stroke 
is a cerebrovascular accident (CVA) that occurs when there is an obstruction of flow in the cerebral 
circulation, which damages the brain (Labarthe, 2011). The classic symptoms of stroke include 
numbness or weakness of the face, arm, or leg, confusion, difficulty with pronunciation, or 
understanding, dizziness, reduced coordination, blurred vision, and a sudden headache. These 
symptoms last for a short period of time and are followed by a sudden loss of consciousness, motor 
and sensory function on one side of the body (Labarthe, 2011). 
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       Environmental factors play a major role in stroke prevalence and those who have had a stroke 
often suffer permanent brain injury, disability, or death. Fortunately, stroke incidence has been 
decreasing in recent years but continues to disproportionately affect non-Hispanic whites in 
mortality rates (Labarthe, 2011). Risk factors for stroke include age, gender (male), race (Black, 
Asian, Hispanic), family history, low birth weight, hypertension and cardiac disease (Wells et al., 
2008), but the most prominent contributor and controllable factor of all types of stroke is high blood 
pressure (Labarthe, 2011). In 2011, 76,400,000 people were living with high blood pressure and 
7,000,000 had strokes (Lopez-De et al., 2010). 
       Similarly to coronary events, stroke has the following common features for clinical and 
biological progression (Figure 2): (Labarthe, 2011)—  
Phase I: Background  
Atherogenesis leads to atherosclerotic lesions in the cerebral arteries or high blood pressure 
or both  
1) Phase II: Acute Events (<24 hours)  
Transient Ischemic Attach (TIA): an episode that ends within 24 hours  
TIA may lead to a recurrent TIA 
2) Phase III: Acute Events (>24 hours) 
Completed stroke: an episode that ends after 24 hours  
3) Phase IV: Medium to late development  
Fatal stroke: a completed stroke that precedes death within 28 days from the episode  
The last phase characterizes short-or long-term outcomes from the first three phases.   
 Background conditions may lead to TIA or completed stroke  
 Acute events (<24 hours) may lead to recurrent TIA or completed stroke  
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 Acute events (>24 hours) may lead to full recovery, residual disability, recurrent 
stroke, and/ or death  
       Stroke is a major public health concern because it is the third leading cause of death in females 
of all races in the US (CDC, 2011). Stroke has many potential manifestations and the most common 
form is the acute event (>24 hours).  
       Strokes diagnostic classification for stroke in population studies includes subcategories of 
stroke (subarachnoid hemorrhage, intracerebral hemorrhage, brain infarction due to occlusion of 
pre-cerebral arteries or due to cerebral thrombosis, and embolic brain function). Studies often 
define stroke disparately and thus the inclusion criteria is necessary to understand the inclusion 
criteria used (Lin et al., 2001; Bier, 2011; Trussell et al., 2009). 
2.6 Definitions  
Perfect use: refers to method failure; it “is a failure inherent to the proper use of the contraceptive 
alone.”  
Typical use refers to user failure and takes into account “the user’s ability to follow the directions 
correctly and consistently.”  
Understanding the distinction between “perfect-use” and “typical use” of the contraception method 
is essential to the contraception literature. Perfect use refers to method failure; it “is a failure 
inherent to the proper use of the contraceptive alone.” Typical use refers to user failure and takes 
into account “the user’s ability to follow the directions correctly and consistently” (Marchbanks et 
al., 2002) 
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2.7 Tables and Figures  
 
Table 2.1 Guidelines for Oral Contraceptive Use Using the US Medical Eligibility 
Criteria for Contraceptive Use (MEC) 
Topic Combined Oral 
Contraceptives  
MEC± Progestin-Only Oral 
Contraceptives 
MEC± 
Age      
< 40 years If other lifestyle factors are 
reviewed, women from 
menarche through 40 years of 
age can use  
1 No restrictions  1 
≥ 40 years Generally use COCs, slightly 
increased risk of adverse 
events 
2 No restrictions  1 
Breastfeeding    
<6weeks PP∞ Should not use this method, 
especially women with risk 
factors for VTE  
4 POCs can be started 
anytime, including 
immediately 
postpartum (MEC 2 is 
< 1 month)  
2 
≥6 weeks to  
<6 months PP 
(Among women with VTEs, 
MEC 4) 
3 MEC 1 ≥ 1 month 
postpartum 
1 
≥6 months PP Generally safe to use if 
women do not have risk 
factors for VTE 
2 Safe to use regardless 
of VTE risk factors  
1 
Non-Breastfeeding women (PP) 
    
< 21 days  
 
 
 
(i) Without other risk factors 
for VTE 
(ii) With other risk factors for 
VTE 
4 
 
3 
(i) Without other risk 
factors for VTE 
(ii) With other risk 
factors for VTE 
1 
 
1 
≥21 days to 42 
days 
(i) Without other risk factors 
for VTE 
(ii) With other risk factors for 
VTE 
2 
 
3 
(i) Without other risk 
factors for VTE 
(ii) With other risk 
factors for VTE 
1 
 
1 
Cardiovascular Disease     
Risk Factors Older age, smoking, diabetes, 
and hypertension  
3/4  1 
Examinations and Tests: blood pressure, baseline weight/ BMI, Clinical Breast Exam (CBE), 
and laboratory tests 
Blood pressure  Should be measured before 
initiating this OC method 
(i) Systolic 140-159 mm Hg 
or diastolic 90-99 mm Hg   
(ii) Systolic ≥ 160 mm Hg or 
diastolic ≥100 mm Hg  
3 
 
 
 
 
4 
No restrictions  1 
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Baseline 
Weight/ BMI 
BMI = ≥ 30 kg/m^2 2  Obese women can use 
POCs 
1  
Hypertension   (i) Women who have more 
severe hypertension (systolic 
pressure of ≥160 mm Hg or 
diastolic pressure of ≥100 
mm Hg) or vascular disease 
should not use combined OC  
(ii) Controlled hypertension 
or  
4 
 
 
 
 
 
 
3 
No restrictions  1 
Clinical Breast 
Exam 
Undiagnosed mass  
Will not detect 
contraindications 
2 Not necessary  1 
Lab Tests     
Other  (i) Complicated diabetes  
(ii) Hyperlipidemias 
depending on the type and 
severity and presence of other 
CVDs 
(iii) Certain liver disease  
(iv) Thrombogenic mutations 
However, screening of 
diabetes, hyperlipidemia, 
liver disease, thrombogenic 
mutations is not necessary/ 
cost-effective  
 
Women with anemia, cervical 
intraepithelial neoplasia, 
cervical cancer, HIV 
infection, or other STDs can 
use (U.S. MEC 1±) or 
generally can use (U.S. MEC 
2±) combined hormonal 
contraceptives 
4 
2/3 
 
 
 
4/3 
4 
(i) Women with 
hypertension, diabetes, 
hyperlipidemia, 
anemia, thrombogenic 
mutations, cervical 
intraepithelial 
neoplasia, cervical 
cancer, STDs, or HIV 
infection can use POCs 
(MEC 1) or generally 
can use POCs (MEC 2) 
(ii) Certain liver disease  
1 
 
 
 
 
 
 
 
 
 
3 
Other Contraindications     
Contraindicatio
ns  
(i) Women with current breast 
cancer  
(ii) Severe hypertension or 
vascular disease 
(iii) Heart disease  
(iv) Migraine headaches with 
aura  
(v) Women ages ≥35 years 
who smoke  
4 (i) Women with current 
breast cancer   
(ii) Migraines with aura 
4 
 
1 
± U.S. Medical Eligibility Criteria for Contraceptive Use (MEC) 1= A condition for which there is no 
restriction for the use of the contraceptive method; 2= A condition for which the advantages of using the 
method generally outweigh the theoretical or proven risks; 3= A condition for which the theoretical or 
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proven risks usually outweigh the advantages of using the method; 4= A condition that represents an 
unacceptable health risk if the contraceptive method is used  
Abbreviations: BMI = body mass index; COC= Combined Oral Contraceptive; POC= Progestin-Only 
Contraceptive; HIV = human immunodeficiency virus; STD = sexually transmitted disease; VTE= venous 
thromboembolic event; PP∞= Postpartum 
 
Table 2.2 Comparison of Oral Contraceptives: Efficacy, Mechanism, Timing and 
Unintended Pregnancies  
 Combined OC Progestin-only OC 
Efficacy 9 out of 100 women become 
pregnant in the 1st year of use  
9 out of 100 women become pregnant in 
the 1st year of use 
Mechanism COCs are reversible and do 
not protect against STDs. 
Consistent and correct use of 
condoms reduces the risk for 
STDs, including HIV 
POCs are reversible and do not protect 
against STDs. Consistent and correct use 
of condoms reduces the risk for STDs, 
including HIV 
Timing Initiated at any time if woman 
is not pregnant; ideally started 
within the first 5 days since 
menstrual bleeding 
Initiated at any time if woman is not 
pregnant; ideally started within the first 5 
days since menstrual bleeding 
Unintended pregnancy¥  
Typical Use*  9.0% 9.0% 
Perfect Use ± 0.3% 0.3% 
*COC: Missed Pill (including vomiting or severe diarrhea) applies only to hormonally active pills (not 
placebo pills); ≥ 24 hours since the pill should have been taken and POCs Missed pill can occur any day of 
the month; no placebo pills; >3 hours since it should have been taken, (Trussell, 2011); ± Women who did 
not miss a pill; Women not using any method of contraception had 85% typical and perfect use; 
¥Percentage of Women Who Experienced An Unintended Pregnancy During The First Year Of Oral 
Contraceptive Use: Typical Vs. Perfect Use (%) 
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Figure 2.1 Common features of coronary events 
 
Figure 2.2 Four phases of Clinical and biological progression of heart diseases  
Background 
condition 
• High blood pressure
• Atherosclerotic lesions in the pre-cerebral and cerebral arteries 
Acute event 
(<24 hours)
• Recurrent TIA
• Transient Ischemic Attack (TIA)
Acute event
(>24 hours)
• Completed stroke 
Medium to late 
development
• Full recovery 
• Residual disability
• Recurrent stroke (>28 days) 
• Death 
Background 
conditions 
• Advanced atherosclerotic lesions in coronary arteries 
• Silent infarction
Initial/ 
Potential 
factors 
• Disruption of surface or fissure of plaque or thrombosis
Acute events
• Symptomatic ischemia
(angina or MI)
• Sudden death 
Medium to 
late 
development
• Disease without symptoms
• Plaque enlargement 
• Recovery without symptoms, stable angina, cardiac dysfunction, short-
term fatality, late recurrence, late coronary death  
Figure adapted from Labarthe 2nd edition page 
61 
Figure adapted from Labarthe 2nd edition page 
61 
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CHAPTER III.  
MATERIALS AND METHODS 
3.1 Introduction  
A population-based retrospective cohort study of the South Carolina (SC) Medicaid administrative 
enrollment and claims data were collected from January 1st, 2000 to December 31st, 2013. All of 
the information was gathered from the Revenue and Fiscal Affairs Office, located in Columbia, 
SC. The Medicaid program provides necessary health care services and other essential resources to 
low-income families who otherwise might not have access to care. SC Medicaid data is a unique 
source of information that represents low-income families and individuals who are 
underrepresented in health research.  
       The primary objective of this study is to compare oral contraceptive (OC) types [combined 
oral contraceptive (COC) or progesterone-only contraceptive (POC)] and evaluate chronic disease 
outcomes (breast cancer, coronary heart disease (CHD), and stroke). We are also interested in 
examining changes in OC use and disease outcome over time. Secondary data analyses were 
performed using the SC Medicaid data set. This original protocol was approved by the Institutional 
Review Board of the University of South Carolina (USC). 
3.2 South Carolina Medicaid  
       Medicaid is a federal and state government program that provides free or low-cost health 
coverage to millions of Americans. It is one of SC’s largest insurance providers for low-income 
people, families and children, pregnant women, the elderly and people with disabilities (Medicaid, 
2015). One fourth of SC residents receive health coverage from SC’s Medicaid comprehensive 
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plan and 43% of SC Medicaid recipients are black (MLTSS, 2015). The distribution of the 
population will allow us to examine underserved populations by race.  
3.3 Research Design, Methods, and Data Analysis  
       Figure 3.1 shows the retrospective cohort design used in this study. The SC Medicaid 
population exposure status was determined through information on oral contraceptive exposures. 
The disease status was determined for exposed and unexposed groups (breast cancer mortality, 
heart disease incidence, and stroke incidence).  
3.3.1 SC Medicaid Population   
       The enrollment period is necessary to capture a complete medical snapshot for each participant 
because women in the Medicaid cohort may alternate between periods of eligibility and 
ineligibility. Women were followed from 01/2000 to 12/2013 and included based on the inclusion/ 
exclusion criteria: 
3.3.1. a Cohort Selection (Inclusion/ Exclusion criteria):  
  Inclusion 
 Permanent residents of SC during study period 
 Among stroke and heart disease cohort: Women aged 18 to 55 
Among breast cancer cohort: Women aged 18 to 65 
 Participants had at least twelve months of Medicaid enrollment during 
study period (01/01/2000- 12/31/2013) 
 Race/ Ethnicity: Black/ African American or white/ European American 
Exclusion 
 Subjects who had a disease diagnosis (breast cancer, heart disease, 
stroke) prior to the study period  (e.g. before 01/2000) 
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The inclusion/ exclusion criteria serves as the basis for the SC Medicaid population (Figure 1).  
3.3.1. b Dataset 
       The Medicaid data set includes information about each participant’s demographic information, 
as well as their medical and pharmacy claims.  
       Demographic information includes current and past educational achievement (less than high 
school, high school, some college, or more than a college degree), marital status (married or not 
married), race (Black/ African American (AA) or White/ European American (EA)), continuous 
eligibility (≥12 months), age (18-65), OC use (yes/no) and type of OC used [progesterone-only oral 
contraceptive (POC), combined oral contraceptive (COC), and POC+COC]. Race was restricted to 
AA or EA because other races were less than 3% of the sample and oral contraceptive use could 
not be adequately stratified by OC type (i.e. low cell count). 
       The pharmacy claims provide information about the drug/ generic name, therapeutic class, age 
at claim, dispensed date (month/year), American Hospital Formulary Service (AHFS) drug codes, 
and type of OC pill used. Norethindrone is the only type of POC used and sold in the Medicaid 
population (Kaunitz 1997; McCann and Potter 1994; FSRH 2009).  
       The medical claims include the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) diagnosis codes, first and last dates of service, Healthcare 
Common Procedure Coding System (HCPCS) codes, primary diagnosis of disease, age at diagnosis 
(years), and disease outcome (breast cancer mortality; and CHD, and stroke incidence).  
3.3.2.  OC Exposure Status 
We classified women as exposed or unexposed based on the following definition:      (Figure 1) 
- Exposed: Exposure to OC is determined by HCPCS code. Drug code/ name and therapeutic 
class listed in Appendix. Recipients are classified by exposure status (COC or POC).  
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- Unexposed: Women who did not have a COC or POC pharmaceutical claim during the 
study period were included in the ‘No OC’ group.  
3.3.1. c Duration of  exposure status  
       To accurately measure adherence and duration of medication use in COC and POC users, we 
calculated the proportion of days covered (PDC) using a macro (%PDC_Change). The macro 
requires defining several parameters: input and output of dataset name, unique patient identifier, 
and prescription fill date, fill days of study period, and end date of study period. The Pharmacy 
Quality Alliance has supported PDC measure as the “preferred method” to calculate medication 
adherence and duration. This method corrects for overestimations noticed in previous methods 
and calculates the true rate of adherence and duration of use. We used % PDC_Change to 
measure the number of days women were covered by a prescription, divided by the number of 
days in the measurement period. The PDC was calculated for each patient during their pregnancy 
prevention period using their drug therapy information. If a woman switched her medication 
during a measurement period, we adjusted accordingly using a modified version of the macro 
(Wang, et al., 2013). 
3.3.2 Disease Status 
3.3.2. a Medicaid ICD-9 codes  
The following ICD-9 codes were used for each disease: 
3.3.2. a. i. Breast Cancer  
A medical claim with an ICD-9-CM diagnosis code of ‘174,’ ‘174.1,’ ‘174.2,’ ‘174.3,’ 
‘174.4,’ ‘174.5,’ ‘174.6,’ ‘174.7,’ ‘174.8,’ ‘174.9,’ ‘233.0,’ ‘238.3,’ ‘239.3,’  These 
classifications represent portions of malignant neoplasm of breast,  carcinoma in situ, 
neoplasms of uncertain behavior, neoplasms of unspecified nature and exclude the skin of 
the breast.  
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 174     Malignant neoplasm of female breast 
o Includes:    breast (female): connective tissue, soft parts;  
Paget's disease of breast and nipple 
 174.0   Malignant neoplasm of Nipple and areola of female breast 
 174.1  Malignant neoplasm of Central portion of female breast 
 174.2  Malignant neoplasm of Upper-inner quadrant of female breast 
 174.3  Malignant neoplasm of Lower-inner quadrant of female breast 
 174.4  Malignant neoplasm of Upper-outer quadrant of female breast 
 174.5   Malignant neoplasm of  Lower-outer quadrant of female breast 
 174.6   Malignant neoplasm of Axillary tail of female breast 
 174.8   Malignant neoplasm of Other specified sites of female breast 
 174.9   Malignant neoplasm of Breast (female), unspecified 
 233.0   Breast 
o 233     Carcinoma in situ of breast and genitourinary system 
 238.3 breast (excludes skin of breast 238.2) 
o 238     Neoplasm of uncertain behavior of other and unspecified sites and 
tissues 
 239.3 breast (excludes skin of breast 239.2)  
o 239 Neoplasms of unspecified nature 
       The sample from Medicaid will be linked to the breast cancer data from the South Carolina 
Central Cancer Registry (SCCCR). Data is linked by last name, date of birth, social security 
number (SSN), and Medicaid number (if provided). The SCCCR is a North American 
Association of Central Cancer Registries (NAACCR) certified population-based registry that 
provides complete, timely, and quality information about cancers. Residents who are not 
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diagnosed or treated in South Carolina are still detected through case-sharing agreements with 
other state cancer registries.  
3.3.2. a. ii. Stroke 
There is a lack of consensus about the proper method to classify stroke patients (Goldstein, 
1998; Roumie et al., 2008). Based on the American Academy of Neurology, Stroke Practice 
Improvement Network (SPIN), American Stroke Association, Georgia Hospital 
Association, and the Joint Commission on Accreditation of Healthcare Organizations, 
stroke is defined using the codes below for ischemic and hemorrhagic strokes (The Joint 
Commission, 2015):  
Ischemic stroke 
o 433.01 occlusion and stenosis of basilar artery with cerebral infarction  
o 433.11 occlusion and stenosis of carotid artery with cerebral infarction  
o 433.21 occlusion and stenosis of vertebral artery with cerebral infarction  
o 433.31 occlusion and stenosis of multiple and bilateral pre-cerebral arteries 
with cerebral infarction  
o 433.81 occlusion and stenosis of other specified pre-cerebral artery with 
cerebral infarction  
o 433.91 occlusion and stenosis of unspecified pre-cerebral artery with cerebral 
infarction  
o 434.00 cerebral thrombosis without mention of cerebral infarction  
o 434.01 cerebral thrombosis with cerebral infarction  
o 434.11 cerebral embolism with cerebral infarction  
o 434.91 cerebral artery occlusion unspecified with cerebral infarction 
o  436 acute, but ill-defined, cerebrovascular disease 
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Hemorrhagic stroke 
o 430 subarachnoid hemorrhage  
o 431 intracerebral hemorrhage  
o 432 other and unspecified intracranial hemorrhage  
o 432.0 nontraumatic extradural hemorrhage  
o 432.1 subdural hemorrhage  
o 432.9 unspecified intracranial hemorrhage 
3.3.3. a. iii. Coronary Heart Disease  
A medical claim with an ICD-9-CM diagnosis code of ‘402,’ ‘410,’ 411,’ 413,’ ‘414,’ and 
‘429’ was considered a claim for CHD. These classifications represent portions of chronic 
myocardial infarction, hypertensive heart disease, acute or subacute forms of ischemic 
heart disease, and other forms of CHD. 
The ICD-9-CM code descriptions are as follows (CMS, 2005):  
 402     Hypertensive heart disease 
o Includes:    hypertensive heart (disease) (failure), and any condition in 428, 
429.0-429.3, 429.8, 429.9 due to hypertension 
o Benign and malignant hypertensive heart disease without and without heart 
failure 
o 402.90/91 Unspecified hypertensive heart disease with and without heart 
failure  
 410    Acute Myocardial Infarction 
 411     Other acute and subacute forms of ischemic heart disease 
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o Coronary: Microinfarction of heart failure, pre-infarction syndrome, 
insufficiency (acute), post- myocardial infarction or intermediate coronary 
syndrome, Dressler's syndrome 
 413     Angina Pectoris 
 414     Other forms of chronic ischemic coronary heart disease 
o Excludes:    cardiovascular arteriosclerosis, degeneration, disease or sclerosis 
(429.2) 
 429.9   Unspecified 
o Includes: Heart disease (organic) NOS and Morbus Cordis NOS 
3.3.3. b Terms (time-to-event, censorship)   
- The event or outcome of interest is: 
o Binary variables: 
 Breast cancer mortality (yes/no)  
 CHD incidence (yes/ no)  
 Stroke incidence (yes/no)  
- If the outcome of interest occurs (‘yes’), the participant has the event or outcome of 
interest. If not (‘no’), the participant did not have an event (Figure 1)  
- Disease status was classified according to ICD-9 codes 
- Time-to-event: the time from entry into the study until a subject has disease of interest 
(breast cancer) 
o The woman is no longer at risk when she experiences the event or is censored  
- Exit date: defined as a date of outcome of interest for the study (breast cancer) or end of 
study period  
- Right Censoring: subjects are censored if they are lost to follow up, or if the study ends 
before they have the outcome of interest  
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o Censoring is independent of disease outcome  
- ‘Any OC’ refers to a woman using any OC (‘POC, COC, or POC+COC’ vs. ‘Never 
User’) 
3.4 Specific Aims  
3.4.1 Specific Aim 1 
- Describe the demographic characteristics of the SC Medicaid recipients  
o Compare and contrast demographic characteristics among Medicaid Participants 
by OC type used (Never use, POC, COC, and POC+COC) 
o Assess frequency distribution/ summary statistics for categorical/ continuous  
- Determine the association between OC users and never users (‘Any OC’ –yes vs. no) 
using logistic regression analysis  
o Compared to the year 2000, we will assess ‘Any OC’ use between 2001 to 2013  
o Calculate the OR and 95% CI for ‘Any OC’ Use, crude and adjusted (age, year, 
race, marital status, education) models 
o Calculate the multinomial logistic regression models predicting the type of OC 
users in the SC Medicaid population among OC users  
o Evaluate trends of prescribing by race over time  
 The interaction of race and time and its association with the type of OC 
used 
 Calculate the annual percent change rate between 2000 and 2013 for 
Medicaid Users (Percent Growth Rate: [(Rate in 2013 minus rate in 
2000) divided by (rate in 2000)] times 100) 
Hypothesis: There is no difference between the type of OC used by race over the years  
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Alternative Hypothesis: There is a significant difference between the type of OC used by race 
over time  
3.4.1. a  Guiding Framework   
For each disease, we will examine OC use by type. Below are 2x2 tables that depict our main areas 
of focus.  
a) Compare ‘Any OC’ Use: POC, COC, or POC+COC vs. Never User  
 
 
 
b) Compare OC users only by type of OC (POC or POC+COC compared to COC) 
 
 
 
 
c) Compare ‘Never User’ to the different types of OC’s (POC/ COC/ POC+COC) 
 
 
 
d) Repeat a-c by race  
3.4.2 Specific Aim 2 
- Compare time-to- mortality distributions of OC users by race (OC use death) 
 Disease No Disease  
Any OC  a 𝑏 
Never user            𝑐 𝑑 
 Disease No Disease  
COC  (ref) (ref) 
POC  a 𝑏 
POC+ COC  𝑐 𝑑 
 Disease No Disease  
Never use   (ref) (ref) 
OC type  a 𝑏 
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o Comparing Never User and ‘Any OC’   
 Null hypothesis: There is no difference between breast cancer mortality 
between Medicaid recipients with or without OC use (H0: S(t) No OC = S(t) 
COC or POC or POC+COC) 
 Alternative hypothesis: There is a difference between breast cancer 
mortality and Medicaid recipients with or without OC use  
(H1: S(t) OC ≠ S(t) COC or POC or POC+COC) 
o Comparing ‘OC Types’  
 Null hypothesis: There is no difference between breast cancer mortality 
between Medicaid recipients receiving different types of OCs (H0: S(t) 
POC = S(t) COC= S(t) POC+COC) 
 Alternative hypothesis: There is a difference between breast cancer 
mortality between Medicaid recipients depending on the type of OC used 
(H1: S(t) POC ≠ S(t) COC ≠ S(t) POC+COC) 
o Comparing ‘Never Users OC’ to ‘OC Types’  
 Null hypothesis: There is no difference between breast cancer mortality 
among Medicaid recipients without prior OC use and OC use (H0: S(t) No 
OC = S(t) COC) and (H0: S(t) No OC = S(t) POC) and (H0: S(t) No OC = S(t) 
POC+COC) 
 Alternative hypothesis: There is a difference between the breast cancer 
mortality among Medicaid recipients with or without prior OC use (H1: 
S(t) No OC ≠ S(t) COC) and (H1: S(t) No OC ≠ S(t) POC) and (H0: S(t) No OC = S(t) 
POC+COC) 
Where S(t) No OC= Time-to-mortality function for women who have never used  
                             OC   
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             S(t) COC= Time-to-mortality function for women who have used  
                            combined OC 
S(t) POC= Time-to- mortality function for women who have used            
                progestin-only OC 
S(t) POC+COC= Time-to- mortality function for women who have used 
both          
                progestin-only OCs and combined OCs 
- Compare each model by race (EA or AA)  
       To observe the relationship between OCs and breast cancer mortality, survival analysis, a non-
parametric method was used to estimate the risk of disease while adjusting for potential 
confounders. Baseline demographic variables were calculated and categorical and continuous 
variables were assessed using chi-square rest and two-tailed t-tests, respectively. POC, COC, and 
POC+COC users were compared; each group are mutually exclusive.  
       Kaplan-Meier survival curves and the log-rank test statistic were used to calculate the 
statistical differences between breast cancer mortality among different OC groups. The Kaplan-
Meier method is a non-parametric maximum likelihood estimator that does not control for 
covariates but can test differences between groups. We calculated the crude differences between 
OC groups given the time-to- breast cancer mortality using the Kaplan-Meier method. Due to 
long latency periods in cancer, we used the log-rank test instead of the Wilcoxon test. The log-
rank test is more powerful than the Wilcoxon test in detecting differences between groups that 
occur at greater intervals.  
       Total survival time was calculated for all subjects as the time from oral contraceptive exposures 
to the time of death or censoring. Using the Lunn McNeil approach to estimate cause-specific 
mortality (breast cancer and other cause mortality), we analyzed the relationship between type of 
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OC use and cause-specific mortality in a competing risk model adjusting for multiple covariates. 
Hazard ratios and 95% CIs were calculated. In the competing risk models, women survival time 
was calculated from type of oral contraceptive exposure to breast cancer mortality and in a separate 
model, from type of oral contraceptive exposure to non-breast cancer deaths, or other causes of 
deaths. Women were censored at either the date of death for their respective model or at the end of 
the study period, whichever occurred first. Separate competing risk models were performed by race 
(EA/ AA), adjusting for other baseline and demographic variables.  
       The univariate Cox proportional hazard (PH) analysis was also used 1) to assess each variables 
impact on the overall risk of developing the outcome and 2) to determine the adjusted time-to-all-
cause mortality curves. The Cox PH regression model is a semiparametric approach that uses the 
Cox partial likelihood method to estimate regression models with censored data. To determine all-
cause mortality, women were followed from OC exposure until any event occurred (breast cancer 
or other cause).  The multivariate Cox PH model  were also used to calculate the hazard ratios 
(HRs) and corresponding 95% confidence intervals for all-cause mortality given that women used 
POCs, COCs, POC+COCs or were never users of OC. We considered the following models: 
- Model 1: The crude model- h(𝑡, 𝑋) = h(t, X)exp[𝛽 ∗ 𝑂𝐶_ 𝑢𝑠𝑒)]  
- Model 2: adjusted for age 
- Model 3: additionally adjusted for possible confounders (education, and marital status)  
       We evaluated PH assumption and the time-dependent relationship between OC exposure and 
all-cause mortality using Cox PH models. The Cox PH model assumes that there is independence 
between the hazard ratio and time. We assessed this assumption by adding time-dependent 
covariates to our model (i.e. interaction term with time in the model), and determined if it was 
significant (p <0.05). Model selection was based primarily on scientific knowledge (previous 
research and hypotheses) and backward selection procedures. All statistical analysis were 
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performed using the Statistical Analysis Systems software (SAS), version 9.4 (SAS Inc., Cary, 
NC) PHREG procedure (SAS, 2012). Statistical significance will be set at alpha level p<0.05 and 
hypotheses will be tested using a 2-sided tail test.  
3.3.3 Specific Aim 3 
       Descriptive analysis were assessed using the Chi-square test for categorical variables and the 
t-test for continuous variables in each study. To observe the relationship between OCs and CVD 
incidence, we used conditional polytomous logistic regression. COC was the referent population 
because of its popularity (large sample size). Models were adjusted for variables related to our 
exposure and outcomes, age, race, education, and marital status. Results were presented as odds 
ratios and 95% confidence intervals. SAS (version 9.4) was used for all investigations, with an 
alpha level of 0.05.  
3.5 Tables and Figures  
 
Figure 3.1 Retrospective cohort design where the outcome, or disease is the time 
between exposure status to disease (breast cancer, heart disease, or stroke) outcome   
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CHAPTER IV. 
TRENDS 
4.1 Abstract1  
       Background: Progestin-only oral contraceptives (POCs) remain unpopular among both 
clinicians and women because of unpredictable changes in future menstrual cycles. However, 
these contraceptive pills may be an alternative for women who are at an increased risk for 
complications related to the use of estrogen-containing oral contraceptives (OCs). 
contraindications to estrogen+ progestin or combined OCs (COCs) are more prevalent in 
theMedicaid population than in the general population. Our study focuses on factors that 
influence (1) women’s choice of any OC, (2) the type of OC used, and (3) trends in OC use.  
       Methods: This is a retrospective, observational study using de-identified information from 
women enrolled in Medicaid from 2000 to 2013 in South Carolina (n=204,762). Logistic 
regression analyses were conducted, adjusting for potential confounders.  
      Findings: POC use was more common among older women (OR: 1.05; 95%CI: 1.04, 1.06) 
and African-American women (OR: 1.09; 95%CI: 1.01, 1.16) compared to COC users. Married 
women were more likely to use POC (OR: 1.31; 95%CI: 1.20, 1.42) and POC+COC (OR: 1.45; 
95% CI: 1.35, 1.55) formulations compared to COCs, but were not significantly more likely to 
use OCs overall (‘any OC’) compared to no OC use (OR: 1.02; 95%CI: 0.96, 1.09). There was an 
increasing trend in POC use over time, especially among European-American women.
                                                     
1 Samson, M., Adams, SA., Zhang, J., Bennett, C., Hebert, JR. (2016) Trends in Oral Contraceptive Use by Race and 
Ethnicity in South Carolina among Medicaid-enrolled Women. Under Revision. 
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       Conclusion: POCs have been associated with less detrimental health effects compared to 
COCs and may be a better alternative to reducing unintended pregnancies among women at high-
risk of certain health complications. The public health community should focus on identifying the 
proper population to use progestin-only pills.  
4.2 Introduction 
       The oral contraceptive (OC) pill remains the preferred method of contraception to prevent 
unintended pregnancies (Jones et al., 2012). The probability of a contraceptive failure within the 
first year of typical use is lowest among injectable users (6.7%, 95% CI: 4.3-10.4) and pill users 
(8.7%, 95% CI: 7.2, 10.5) (Trussell, et al., 2009). Due to their high effectiveness and marketing 
efforts, OCs have remained popular since the 1960s. However, most OC users are typically 
prescribed combined OCs (COCs), which contain both estrogen and progestin hormones. Despite 
reductions in estrogen dose in modern COCs, there is still controversy about the risks associated 
with COC use (ASRM, 2008; O’Brien 1999). Women using COCs with small doses of estrogen 
may still suffer clinically relevant side effects, such as abdominal or chest pain, headaches, eye 
problems, and/ or swelling of legs and thighs (Dawson, 1979), which may indicate a more serious 
problem, such as venous thromboembolism (VTE) (Hall et al., 2012), liver disease, gallbladder 
disease, stroke, high blood pressure, or heart disease (Wolski, 2014; Dawson, 1979; Curtis, 2010). 
These risks are reduced among progestin-only oral contraceptive (POC) users (Mantha et al., 
2012). Furthermore, studies have shown that POCs have similar effectiveness as COCs 
(Contraceptive Technology, 1999; Trussell 2011).  
       Despite similar effectiveness, POCs remain unpopular among women (Grimes et al., 2013). 
Physicians may be less likely to prescribe POCs to women because of POCs mechanism of action 
which may disrupt the normal menstrual patterns (Grimes et al., 2013). To overcome a significant 
barrier to progress in women’s health, we must understand factors that influence women’s choice 
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of OC specifically by type (POC, COC, and POC+COC) of OC used.  Given that approximately 
70 million women in the United States are currently in their childbearing years (15-44 years of 
age) and of those participating in sexual intercourse, more than 99% have used at least one 
contraception method (barrier, hormonal, intrauterine, and/or sterilization), often in combination 
with one another (Dye, 2008; Jones et al., 2012). It is imperative that research continues to 
identify healthier alternatives to COCs for pregnancy prevention and family planning.  
       Contraindications to COC use include tobacco smoking, obesity, and certain cardiovascular 
diseases (Curtis 2010). The presence of these contraindications are more common among low-
income, or Medicaid recipients (Armour et al., 2009; Lee et al., 2010; Mateen et al., 2014). 
Furthermore, minority women and women earning less than 150% of the federal poverty line 
(FPL) are least likely to be aware of OC use guidelines (Dehlendorf et al., 2010). Among women 
who are at increased risk of complications due to estrogen, POCs are the preferred OC choice. 
However, factors influencing the use of OCs among these groups are understudied. South 
Carolina Medicaid administrative claims contain records of women’s OC type used, age, calendar 
year of use, race, and marital status, from 2000 to 2013. Information on other contraceptive 
methods were excluded due to the popularity of OC use. We, used these data to (1) identify 
factors that influence any use of OC (yes or no) (2) identify factors that influence women’s 
choices of contraception (POC, COC, POC+COC) in  a diverse cohort of women typically under-
represented in the literature, and (3)  examined trends in OC medication use over time among SC 
Medicaid population from 2000 to 2013. 
4.3 Materials and methods 
Study Design and Setting  
       We conducted a retrospective analysis of SC Medicaid claims data to determine factors that 
influence OC use and to examine the trends in OC use from 2000 to 2013. This study was 
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conducted after receiving approval from the Institutional Review Board of the University of 
South Carolina. 
Data Sources and Participants 
       The South Carolina Office of Research and Statistics (ORS) provided us demographic, 
medical, and pharmacy claims data for Medicaid patients between 2000 and 2013. Pharmacy 
claims, classified by the National Drug Code (NDC), supplied information on prescription drugs 
dispensed for contraception purposes (e.g. POC, COC). Study participants were located by 
searching Medicaid administrative database and identifying NDC codes related to the type of OC 
drug (therapeutic class: 681200). Criteria for inclusion in the analysis were as follows: (1) ≥ 18 
years, ≤ 65 years, (2) African American (AA) or European American (EA), (2) sex (female only), 
and (3) ≤ 12 months of continuous Medicaid enrollment between January 1st, 2000 through 
December 31st, 2013. Our analysis included 204,762 women.  
Covariate Classification 
       Demographic data were obtained from Medicaid files. Age, in years, was determined as of 
January 1st, 2000 and assessed as a continuous variable. Calendar year of OC use was used as 
continuous or categorical variable where appropriate. Women were categorized by marital status 
(yes/ no), educational attainment (< high school/ some high school/ high school graduate/ > high 
school), race (EA/ AA), ‘any OC’ use (yes/no), and type of OC (progestin-only (POC)/ estrogen 
+ progestin (COC)/ POC + COC). Type of OC use were mutually exclusive.   
        ‘Any OC’ users were women who used either POC, COC, or POC+COC and were 
compared to women who never used OCs. However, never users were excluded from the study 
when comparing factors that influenced the type of OC use and assessing the trends of OC use 
from 2000 to 2013.  
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Statistical Analysis 
       Standard univariate and other descriptive statistics were used for all study covariates. We fit 
various regression models to the data in order to understand the subjects’ OC utilization: (1) 
logistic regression was used to examine the factors influencing a woman’s decision to use ‘any 
OC’ (yes/ no) for the entire study sample; (2) a conditional polytomous logistic regression was 
used to discern variables influence on a woman’s choice of OC (POC/ COC/ POC+COC); and (3) 
calculated rates of OC use during the period 2000-2013 by race.  
       For logistic regressions, backward stepwise selection procedures were used to predict the 
relevant variables. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated. The risk 
factors studied were age, race, marital status, calendar year, and education level. Conditional 
polytomous logistic regression was used to predict factors affecting the type of OC use; COC 
users were the referent population.  
       Never users of OC were excluded when comparing factors that influenced the type of OC use 
and assessing the trends of OC use from 2000 to 2013. Rates of OC use were calculated per 1,000 
persons. Annual percentage change rates (PCRs), calculated as the (Rate in 2013 minus rate in 
2000) divided by (rate in 2000)] times 100, were considered to increase or decrease if the p-value 
was <0.05. All statistical analyses were conducted using SAS® version 9.4 software (NC, USA). 
For all calculations, statistical significance was defined by P-values < 0.05.  
4.4 Results 
Study Population 
       A total of 204,762 women were included in the study. For each year, the population was 
predominantly African American (>50%), OC users (>80%), and unmarried (>70%). Due to the 
high variability in Medicaid eligibility per year, we displayed the results per year (Table 1). 
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Among OC users, the majority of women used COCs (>60%/ year) and the mean duration of OC 
use was 16.2 (10.6) overall. From 18.4 (8.0) months in 2000 the use decreased to 14.3 (10.4) 
months in 2013. Since 2000, there also are fewer women reporting more than a high school 
degree, from 57.6% to 12.6%, and more women reporting less than a high school education, from 
19.3% to 62.2%. The mean age of women in the sample decreased from 27.9 (6.3) years in 2000 
to 24.3 (6.7) years in 2013 (Table 1).    
Any OC Use  
       There was a 2-4% increase in the odds of using any OC (POC/ COC/ POC+COC) per year, 
adjusting for other important variables. The odds of using any OC was similar in 2000 and 2013 
(odds ratio (OR): 1.02; 95% CI: 0.88, 1.17). However, compared to the year 2000, there was a 
significant decrease in the odds of using any OC from 2001 to 2003.  After reaching a nadir in 
2003, the odds of using any OC began increasing in 2004, culminating in a return to 2000 levels 
in 2013, (all odds ratios adjusted for covariates) (Figure 1).  
       Similarly, after adjusting for age, race, marital status, education, and year, we observed an 
increased odds of using any OC among all women (OR: 1.07; 95% CI: 1.06, 1.07) with every unit 
increase in age. AA women had greater odds of using any OC than EA women in our sample 
(OR: 1.45; 95% CI: 1.38, 1.53). Furthermore, compared to having less than a high school 
education, high school graduates and those with more than a high school degree were 
significantly less likely to use an OC (OR: 0.75; 95% CI: 0.70, 0.81 and OR: 0.89; 95% CI: 0.83, 
0.95, respectively). Being married did not significantly affect the odds of using any OCs (OR: 
1.02; 95% CI: 0.96, 1.09) (Table 2). 
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Type of OC 
       Trends. Figure 2 shows the types of OCs used by race excluding never users. Among women 
using OCs, the majority were COC users. Among COC users, AA women experienced a 
significant decrease in use from 2000 to 2013 time (Percent change rate (PCR): -1.28%), whereas 
EA women’s rate of use remained relatively stable over time (p-value: 0.48) (Table 3). Over this 
period, the rate of POC and POC+COC use significantly increased for EA women (PCR: 10.78% 
and 6.32%, respectively) (Figure 2a). Use of POC+COC in AA women did not increase 
significantly from 2000 to 2013 (PCR: 3.80; p-value: 0.96) (Table 3) but from 2002 to 2013, 
there was a significant increase in POC+COC among AA women (PCR: 11.2%) (Figure 2b). 
There was a significant increase in POC use among AA women (PCR: 3.56%) from 2000 to 
2013. Changes per year were also computed to show significant variations per year (Table 3b). 
The greatest variation were among never users, sometimes varying more than 20% on a yearly 
basis. Among OC users, the highest fluctuations were among POC users whereas AA women had 
greater yearly variations in the POC+COC group.  
       The multivariable-adjusted conditional logistic regression examining the factors that affect 
the type of OC use (POC/ POC+COC) compared to COC, are presented in Table 4. There was a 
significant increase in the odds of POC and POC+COC use from 2001 to 2013, compared to 
2000, adjusting for other variables. Furthermore, AA women had higher odds of POC and 
POC+COC use compared to EA women (OR: 1.09; 95% CI: 1.01, 1.16 and OR: 1.09; 95% CI: 
1.02, 1.15, respectively). Being married also increased the odds of POC and POC+COC use by 
approximately 30-45%. Compared with having less than a high school education, having at least 
some high school experience increased the chances of POC and POC+COC use (OR: 1.12; 95% 
CI: 1.02, 1.23 and OR: 1.26; 95% CI: 1.16, 1.37, respectively). However, having a high school 
education or more reduced the probability of using either POC or POC+COC. Age was associated 
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with a significantly increased odds of POC and POC+COC use. The point estimates and 95% CIs 
of POC and POC+COC use, adjusted for race, marital status, education, and age show a slightly 
higher increase in POC use compared to POC+COC use since 2000 (Figure 3).   
4.5 Discussion 
       Our study confirms that there is an increase in overall OC use over time despite a reduction 
in COC use, especially among AA (p-value: <0.01 vs 0.47 in EA women). The gradual reduction 
in COC use observed among AA women from 2000 to 2012 approaches typical rates of COC use 
among EA women (300-400/ 1,000) from 2000 to 2013. Unlike previous studies focusing on 
women’s health in the general population (DHHS, 2010; Jones, 1999; Daniels, et al., 2013), AA 
women on Medicaid were more likely to use OCs compared to their EA counterparts. The higher 
rates of OC use among AA were driven by the popularity of COC use (EA: 83.43% vs. 85.34%); 
EA women were more likely to use POCs (7.59% vs. 6.64%) and POC+COCs (8.98% vs. 8.01%) 
compared to AA women. Additionally, the increase in POC use over time was significantly 
higher among EAs compared to AAs (10.78% vs. 3.56%, respectively). From 2000 to 2012, there 
was a 14.90% increase rate of POC use among EA women; however, the use of POCs decreased 
slightly from 2012 to 2013.  
       The differences in OC use by race may be due to increased recommendation by physicians 
(Yee et al., 2011), reduced sterilization rates among females (Daniels et al., 2013) and our study’s 
focus on low-income populations. Among Medicaid participants, EA women may be more likely 
to use female sterilization than AA women (K. White et al., 2014), which may explain small 
differences in OC use. Potential reasons for the decline in COC use among AA women may 
include being/seeking to become pregnant, physician prescription changes due to estrogen 
contraindications, and use of alternative contraceptive methods. Oddly, more education was 
inversely related to OC use in our study. This inverse relationship may be due to various reasons: 
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1) lack of adequate information of education in our study population and/ or 2) women with 
higher educational status using different methods of contraception (e.g. depot 
medroxyprogesterone acetate (DMPA), intrauterine devices). More information about education 
status in this population may be necessary to interpret these findings thoroughly. When we 
excluded education from our analyses, our results (point estimates and confidence intervals) did 
not significantly change. Therefore, sensitivity analyses confirmed the stability of our results.  
       Contraceptive methods are continuing to remain a popular option for family planning and 
pregnancy prevention. It is important to understand the underlying reasons that may influence a 
user’s choice of OC method. Analyzing type of OC is often restricted to COCs, which have a 
much more narrow medical eligibility criteria compared to POCs, based on the World Health 
Organization’s (WHO) guidelines (Curtis 2010). There are many benefits to using COCs 
(Brynhildsen, 2014; Spencer et al., 2009; AAFP, 2015); however, many contraindications to 
COC use are prevalent in the general population and particularly in the Medicaid population 
(Armour et al., 2009; Mateen et al., 2014; Lang et al., 2015; Byrne et al., 2014; Flattau et al., 
2011; Orsi et al., 2010; R. H. White et al., 2009). In addition, this study population is susceptible 
to societal barriers that can reduce proper communication with physician (Flattau et al., 2011; 
McDoom et al., 2012; Epstein et al., 2007).  Cardiovascular events among COC users who 
smoked could account for 80% of cardiovascular deaths among women aged 20-24 years (Farley 
et al., 1998); however, incidence of fatal cardiovascular events remained low among women less 
than 35 years old. 
       Clinicians and researchers must pay particular attention to contraindications that are common 
in the population. In our population, more than 28.7% of COC users used tobacco products. 
Common contraindications to COC use include breastfeeding; smoking any cigarettes; risk 
factors for cardiovascular disease (older age, smoking, diabetes, hypertension); VTE; current 
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and/or history of ischemic heart disease or stroke; migraines with aura; inflammatory bowel 
disease; and gallbladder disease, among others (MMWR, 2010). POC formulations have 
significantly fewer contraindications (MMWR, 2010b). Counseling of OC options should be 
emphasized to reduce the possibility of side effects.  
       In the context of our findings, these contraindications highlight the importance of 
understanding the factors that influence women’s decisions to use certain types of OCs. 
Communication with physicians and being informed about the health risks and benefits of each 
type of OC is a major contributor to OC choice (Merki-Feld et al., 2012), in addition to age, race, 
and marital status. The high prevalence of certain illnesses in the Medicaid population highlights 
the importance for physicians and women to consider using POCs as an alternative to COCs. 
There are many women who do not consider the majority of these contraindications when 
choosing the proper contraceptive method, which make them more liable to suffer short- and 
long-term side-effects.  
4.6 Strengths and Limitations 
       Our sample population is restricted to Medicaid enrollees, which provided us with a 
relatively homogeneous population. Though this may limit the generalizability of the study, it 
does provide us unique insight into an under-researched population. Furthermore, it may be that 
patterns seen in the general population may not be observed in the Medicaid population; thus, this 
study may help us adapt recommendations and policies specifically to these groups. Another 
strength of our study is the large sample size, which resulted in a high level of statistical power. 
We used information from administrative claim records, which reduced the potential of bias (e.g. 
self-report). The major limitation of this study is that we do not have information on physician 
prescription patterns, which could further influence OC patterns and use.   
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4.7 Implications for Practice and/or Policy  
       Given the prevalence of OC use by women in the United States every year, understanding the 
patterns of use, especially among underserved populations, is essential. Many women are 
unaware that POCs are an alternative to COCs, despite POCs having less contraindications 
(Mantha et al., 2012). Several implications for practice and policy emerge from this study, such 
as 1) ensuring women of childbearing age who are considering OCs are given additional 
information on the various types of OCs and their benefits and risks; 2) encouraging patient-
physician communication to provide more information related to reproductive healthcare; and 3) 
acknowledging racial/ethnic differences which may exist when counseling on reproductive 
options. Furthermore, women are demanding OCs be offered over-the-counter, which raises 
safety concerns among health care providers (Howard et al., 2013). Over-the-counter availability 
of POCs may be a safer alternative to COCs, which may require women to self-screen for many 
diagnosed and undiagnosed contraindications. Similar studies may highlight additional need for 
practitioners to modify prescription patterns and recommendations depending on women’s 
understanding of reproductive health information and perceived risk (e.g. geographic location, 
family history).  
4.8 Conclusion 
       In conclusion, our data obtained from the Medicaid registry showed an increasing trend from 
2000 to 2013 in OC use overall with a slight decrease of COC use among AA women and an 
increase in POC and POC+COC in both AA and EA women, albeit to varying extents by race. 
Information about oral birth control  options need to  be  examined and discussions with health 
care providers need to highlight the benefits of POC, COC and possibly switching from COC to 
POC after a couple of years, depending on the presence of new risk factors (e.g. increased blood 
pressure, increased age, diabetes status). It is important for women to understand which OC is 
best for them and when to initiate a new contraceptive method. Future studies should evaluate the 
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presence of each contraindication in the Medicaid population and assess how many women are 
using a pill despite a present contraindication. Providing quality and patient-centered women’s 
healthcare requires increased communication between health provider and patient about possible 
underlying conditions and alternative types of OCs.
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4.9 Tables and Figures  
Table 4.1 Characteristics of Medicaid Participants, 2000-2013  
 
OC Use OC Type  Race Education 
Marital 
Status 
Age Duration 
Year  
 
N(%)/ 
Mean 
(SD) 
No  Yes  
Never 
Use  
POC COC 
POC 
+ 
COC 
 
 
EA AA < HS 
Some 
HS 
HS 
Grad 
> HS No Yes (SD) (SD) 
2000 
N= 
8859 
611 8248 611 299 7469 480 3997 4597 965 167 967 2895 6153 2540 27.9  18.4  
 % 6.9 93.1 6.9 3.4 84.3 5.4 46.5 53.4 19.3 1.2 7.0 57.6 70.8 29.2 (6.3) (8.0) 
2001 
N= 
9299 
772 8527 772 423 7533 571 4220 4778 1370 210 886 2532 6383 2579 27.8 17.1  
 % 8.3 91.7 8.3 4.6 81.0 6.14 46.9 53.1 27.4 4.2 17.7 50.7 71.2 28.8 (6.4) (12.0) 
2002 
N= 
1060
4 
1448 9156 1448 565 7910 681 4775 5465 1447 355 941 2297 7392 2799 27.5  17.1  
 % 13.7 86.3 13.7 5.3 74.6 6.42 46.6 53.4 28.7 7 18.7 45.6 72.5 27.5 (6.4) (28.3) 
2003 
N= 
1185
0 
2072 9778 2072 653 8368 757 5479 5934 1471 472 940 1946 8468 2976 27.1  17.6  
 % 17.5 82.5 17.4 5.51 70.6 6.39 48.0 52.0 30.5 9.8 19.5 40.3 74.0 26.0 (6.4) (5.2) 
2004 
N= 
1168
1 
2076 9605 2076 705 8050 850 5484 5761 1397 536 819 1564 8551 2858 27.0  18.0  
 % 17.8 82.2 17.8 6.04 68.9 7.28 48.8 51.2 32.4 12 19 36.2 75 25 (6.5) (5.0) 
2005 
N= 
1199
9 
1983 10016 1983 748 8281 987 5533 5964 1544 709 817 1468 9034 2718 
26.9 
(6.6) 
16.9  
 % 16.5 83.4 16.5 6.23 69.0 8.23 48.1 51.9 34.0 15.6 18 32.3 76.9 23.1 (6.6) (6.3) 
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2006 
N= 
1163
2 
1616 10016 1616 665 8395 956 5362 5792 1573 742 725 1207 8493 2494 26.4  15.3  
 % 13.9 86.1 13.9 5.7 72.1 8.2 48.1 51.9 37.0 17.5 17.1 28.4 78.2 21.8 (6.5) (7.9) 
2007 
N= 
1167
1 
1422 10249 1422 697 8555 997 5415 5754 1649 856 641 1056 9154 2350 26.3  16.3  
 % 12.2 87.8 12.2 6.0 73.3 8.5 48.5 51.5 39.2 20.4 15.3 25.1 79.6 20.4 (6.5) (4.2) 
2008 
N= 
1285
4 
1589 11265 1589 785 9429 1051 5924 6361 1826 1030 606 1046 
1018
1 
2530 26.0  15.3  
 % 12.4 87.6 12.4 6.1 73.4 8.2 48.2 51.8 40.5 22.9 13.4 23.2 80.1 19.9 (6.5) (37.5) 
2009 
N= 
1581
6 
1930 13886 1930 1004 
1151
6 
1366 7191 7868 2565 1240 762 1091 
1279
4 
2876 25.4  16.3  
 % 12.2 87.8 12.2 6.4 72.8 8.64 57.8 52.2 45.3 21.9 13.5 19.3 81.7 18.4 (6.2) (1.5) 
2010 
N= 
1774
5 
2116 15629 2116 1154 
1295
5 
1520 8311 8487 2983 1461 749 1110 
1435
4 
3218 25.1  15.0  
 % 11.9 88.1 11.9 6.5 73.0 8.57 49.5 50.5 47.3 23.2 11.9 17.6 81.7 18.3 (6.2) (5.6) 
2011 
N= 
2131
4 
2302 19012 2302 1609 
1586
9 
1534 9986 10170 3730 1534 755 1197 
1760
5 
3442 24.8  14.7 
 % 10.8 89.2 10.8 7.6 74.5 7.2 49.5 50.5 51.7 21.3 10.5 16.6 83.7 16.4 (6.3) (7.3) 
2012 
N= 
2277
6 
2005 20771 2005 1769 
1731
2 
1690 
1085
4 
10641 4308 1512 758 1121 
1904
1 
3382 24.7  14.6  
 % 8.8 91.2 8.8 7.8 76.0 7.4 50.5 49.5 56.0 19.6 9.9 14.6 84.9 15.1 (6.5) (9.1) 
2013 
N=26
662 
2039 24623 2039 1957 
2078
1 
1885 
1196
7 
13116 5875 1653 751 1189 
2289
8 
3279 24.3 14.3 
 % 7.7 92.4 7.7 7.3 77.9 7.1 47.7 52.3 62.1 17.5 7.9 12.6 87.5 12.5 (6.7) (10.4) 
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Table 4.2 Logistic Regression Models Predicting ‘Any OC Use’ in South Carolina 
Medicaid population, 2000-2013 
 Logistic regression predicting the use of any 
OCs* 
Model and 
outcome variable 
covariates 
OR a 95% CI b 
Age d 1.07‡ 1.06, 1.07  
 
Year   1.03‡ 1.02, 1.04 
Race   
  EA 
  AA 
(ref) 
1.45‡ 
(ref) 
1.38, 1.53 
Marital status    
  No  
  Yes  
(ref) 
1.02 
(ref) 
0.96, 1.09 
Education    
 < High school 
Some high school 
High school 
graduate 
> High school  
(ref)  
0.98 
0.75‡ 
0.89‡ 
(ref)  
0.92, 1.05 
0.70, 0.81 
0.83, 0.95 
* Models were adjusted for age, race, year, marital status, and education level;  
a Odds Ratio; ‡ p-value < 0.05; b Confidence interval (95%) 
 
 Table 4.3 Percent Change Rate (PCR) between 2000 and 2013, Medicaid Users in 
South Carolina  
  European American  African American 
OC Type Percent Change 
Rate* 
P-value Percent Change 
Rate* 
P-value 
None  0.85* 
 
<0.01 -2.36* 
 
0.01 
 
POC 10.78* 
 
<0.01 3.56* <0.01 
COC -0.21 
 
0.48 -1.28* <0.01 
POC+COC 6.32* 0.02 3.80 0.96 
*Percent Change Rate: [(Rate in 2013 minus rate in 2000) divided by (rate in 2000)] times 100. 
 
 
 
 
 
  
84 
 
Table 4.4 Percent Change Per Year Intervals Between 2000 and 2013, Medicaid 
users in South Carolina  
 European American African American 
OC Type 
                       
          
Year  
None  POC COC POC+
COC 
None  POC COC POC+
COC 
2000-2001 24.30 36.05 -3.78 23.30 8.28 8.36 -4.76 15.88 
2001-2002 84.52 8.09 1.19 10.40 47.84 6.49 -1.76 -83.87 
2002-2003 16.26 7.48 1.65 9.04 8.75 0.74 -4.38 47.38 
2003-2004 1.261 7.16 -0.93 9.30 -10.03 6.41 -3.98 29.11 
2004-2005 -11.83 -1.66 3.66 8.95 -14.02 -10.13 0.02 11.71 
2005-2006 -11.00 -14.39 3.86 0.31 -12.07 -11.33 0.61 20.04 
2006-2007 -10.84 6.511 -2.22 13.77 -12.98 14.95 0.41 12.81 
2007-2008 -1.62 -1.97 2.81 -1.69 -4.73 -4.17 -2.06 13.23 
2008-2009 -0.62 6.86 -0.15 1.51 -6.54 3.81 -1.63 18.17 
2009-2010 -4.54 16.83 0.87 1.80 -8.68 -3.12 -1.62 7.71 
2010-2011 -20.03 32.33 -7.62 1.47 -7.87 31.44 -6.17 99.53 
2011-2012 -20.69 19.78 0.35 -3.83 -16.39 4.39 -1.15 8.48 
2012-2013 0.05 -14.83 -2.00 -5.77 3.78 0.03 7.57 -8.70 
 *Percent Growth Rate: [(Rate in year (x) minus rate in previous) divided by (rate in previous)] 
times 100 
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Table 4.5 Multinomial Logistic Regression Models Predicting ‘Type of OC Use’ in 
South Carolina Medicaid population Among OC users,  2000-2013  
 Oral Contraceptives 
 COC § POC‡ POC+ COC ± ‡ 
 
Covariates N N OR a 95% CI b N OR a 95% CI b 
Year     P-trend:  <0.01 P-trend: <0.01 
2000 7469 
 
299 
 
1.00  480 1.00  
2001 7533 423 1.35 1.09,1.68 571 1.23 1.03,1.47 
2002 7910 565 1.74 1.41,2.15 681 1.31 1.09,1.56 
2003 8368 653 1.57 1.26,1.95 757 1.30 1.09,1.56 
2004 8050 705 1.75 1.41,2.18 850 1.81 1.52,2.16 
2005 8281 748 1.85 1.49,2.30 987  1.84 1.55,2.19 
2006 8395 665 1.74 1.39,2.17 956 1.89 1.58,2.25 
2007 8555 697 1.74 1.39,2.16 997 1.96 1.65,2.33 
2008 9429 785 1.92 1.55,2.38 1051 1.80 1.51,2.15 
2009 11516 1004 2.01 1.64,2.47 1366 1.97 1.66,2.32 
2010 12955 1154 1.89 1.54,2.32 1520 2.02 1.71,2.37 
2011 15869 1609 2.51 2.07,3.04 1534 1.77 1.50,2.09 
2012 17312 1769 2.46 2.03,2.98 1690 1.82 1.55,2.15 
2013 20781 1957 2.43 2.01,2.93 1885 1.81 1.55,2.12 
Race        
  EA 70664 6427 1.00  7603 1.00  
  AA 74801 5824 1.09 1.01,1.16 7021 1.09 1.02,1.15 
Married         
  No  121,430 9375 1.00  10859 1.00  
  Yes  27914 3517 1.31 1.20,1.42 4351 1.45 1.35,1.55 
Educatio
n  
       
<High 
school 
25229 1705 1.00  2156 1.00  
 Some 
High 
School  
9379 684 1.12 1.02,1.23 940 1.26 1.16,1.37 
High 
School 
Graduate 
8380 557 0.85 0.77,0.95 801 1.12 1.02, 1.23 
>High 
school  
16816 1107 0.79 0.72,0.86 1618 0.79 0.73,0.85 
Age 
(years) 
152,423 1303
3 
1.05 1.04,1.06 15325 1.07 1.06,1.07 
* Adjusted for age, race, calendar year, marital status, and education level using conditional polytomous logistic model, 
‡ p-value < 0.05; ± Mutually exclusive group (does not include either POC or COC users), a Odds Ratio; b Confidence 
interval (95%); § Referent group 
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*Odds Ratio of ‘Any OC’ use compared to no ‘OC use’ adjusted for age, race, marital status, 
education, and year; Referent year 2000 for any OC use compared to No OC use; p-value > 0.05 
if OR > 1 
Figure 4.1 Association between year and ‘Any OC’ use (Odds Ratio and 95% 
Confidence Interval), South Carolina Medicaid Participants, 2000-2013 
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Figure 4.2 Trends in Oral Contraceptive use by Race and Type of Oral 
Contraceptive for European-American (top) and African American (bottom), South 
Carolina Medicaid Participants, 2000-2013 
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Figure 4.3 Association of Year and Type of OC Use (Odds Ratios and 95% CIs) 
South Carolina Medicaid Participants, 2000-2013. Referent group: COC Users; 
Adjusted for calendar year, race, marital status, education, and age 
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CHAPTER V. 
ORAL CONTRACEPTIVES AND BREAST CANCER MORTALITY 
5.1 Abstract 2 
       Introduction: Oral contraceptive pills have been implicated in the pathophysiology of breast 
cancer. Although many studies have examined the relationship between combined oral 
contraceptives (COCs) and breast cancer, there is a paucity of literature that discusses progestin-
only oral contraceptives (POCs) and breast cancer. The purpose of this investigation is to 
examine the association of oral contraceptives by type and breast cancer mortality in the South 
Carolina Medicaid population among different racial/ethnic groups.  
      Methods: Subjects included 4,816 women diagnosed with breast cancer between 2000 and 
2013. Kaplan-Meier curves were calculated to determine time-to-mortality rates among oral 
contraceptives users. Competing risks models were used to estimate the hazard ratios (HR) and 
95% confidence intervals (CI) of breast cancer and other cause mortality.  
      Results: POCs were significantly associated with a decreased risk of breast cancer mortality 
(HR: 0.07; 95% CI: 0.01, 0.52) and a non-significant decreased risk of all-cause mortality (HR: 
0.81; 95% CI: 0.41, 1.59). COCs increased the risk of breast cancer mortality (HR: 1.61; 95% CI: 
1.14, 2.28) and all-cause mortality (HR: 2.19; 95% CI: 1.81, 3.86). 
       Conclusion: Use of POCs may be associated with a decreased risk of breast cancer mortality 
and should be considered as an alternative to COCs among high risk populations.
                                                     
2 Samson, M., Adams, SA., Zhang, J., Bennett, C., Hebert, JR. (2016) The Association of Different Types of Oral 
Contraceptives and Breast Cancer Mortality: A Competing Risk Model. Under Revision. 
   
95 
  
5.2 Introduction 
       Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-
related deaths among women (ACS, 2015). In 2015, approximately 30% of new female cancer 
cases were located in the breast. Reproductive factors, such as oral contraceptive (OC) use, late 
pregnancy, and nulliparity, as well as genetic factors, family history, and age, increase breast cancer 
risk (ACS, 2015; DHEC, 2015; Kumle et al., 2002; Anders et al., 2009; Carey et al., 2006). There 
are currently approximately sixty-two million women in their childbearing years (15-44 years of 
age) and it is reported that more than 99% of those who are sexually active have used at least one 
contraception method during their lifetime (Dye, 2008). Contraceptive pills, specifically combined 
(estrogen+ progestin) oral contraceptives (COCs), and sterilization are the leading methods of 
choice (Daniels et al., 2013). Since the introduction of the birth control pill in the 1960’s, there has 
been a lot of debate about COCs potential health effects (Anders et al., 2009; Hall et al., 2012). 
With the increasing popularity of OCs, it is important to focus on the potential health risks they 
may have on society and to consider ways of reducing these risks.  
       In the National Survey of Family Growth (NFSG), three-fourths of American women who used 
a contraceptive method reported using OCs. Of those currently using an OC method, 98% used a 
COC method, and 2% reported using progestin-only contraceptive pills (POCs) (Hall et al., 2012).  
Within one year of use, similar rates of unintended pregnancies are observed among COC and POC 
users with typical and perfect use (9 cases/ 100 women and 3 cases/ 1000 women, respectively) 
(Carey et al., 2006; NCI, 2015). Typical use refers to pregnancy rates that include inconsistent or 
incorrect use and perfect use applies to pregnancy rates that reflect women following the directions 
(e.g. no missed pill) (Trussell, 2011).  In fact, both COCs and POCs are more than 99% effective 
(Hussain, 2004; Kumle et al., 2002; Trussell, 2015). However, COCs are associated with an 
increased risk of venous thromboembolic events (VTEs), high blood pressure, and breast cancer 
(Daniels et al., 2013; Hussain, 2004; Kubba, 2003; FSRH, 2009). Compared to women who had 
   
96 
  
exclusively used POCs, exclusive users of COCs had a 30% increased risk of breast cancer (Kumle 
et al., 2002). Despite similarities in efficacy and increased risks of adverse effects, COCs remain 
more popular than POCs. Plausible reasons for the existing disparities in OC use include physician 
prescription patterns, knowledge and attitudes of OC types, longer biological adjustment periods 
(Kovacs, 1996) and lack of communication between provider and patient.  
       Many studies have investigated whether COCs increase the risk of breast cancer (Hunter et al., 
2010; Longman et al., 1987; Beaber et al., 2014); however, there is a paucity of literature assessing 
different types of OCs (non-estrogen-containing formulations) and breast cancer risk. Due to 
significant health disparities in breast cancer mortality among African American (AA) and 
European American (EA) women, and potential differences in types of OCs used between races, 
we will focus on the differences in breast cancer mortality by race. South Carolina can provide 
insight into potential reasons for racial/ethnic disparities in cancer mortality, with EA women 
having a higher incidence of breast cancer yet higher survival than their AA counterpart. The 
purpose of this study is to determine the association between the type of OC use and breast cancer 
mortality in the South Carolina Medicaid population using a competing risk model (Kubba, 2003). 
Secondary goals include assessing type of OC use and all-cause mortality as well as mortality from 
other (or “non-breast cancer”) causes. 
5.3 Methods 
Data Sources and Study Design 
       All data used for this analysis were collected through the Office of Research and Statistics 
(ORS)/ SC Revenue and Fiscal Affairs Office (RFA) Medicaid administrative enrollment and 
claims data and linked to the South Carolina Central Cancer Registry (SCCCR) using 
probabilistic matching techniques. The SCCCR maintains a gold-certified rating through the 
National Association of American Cancer Registries (NAACR), indicating data of exceptionally 
high quality, validity, and completeness. Data was linked by matching on name, social security 
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number (SSN), and other identifying variables. This study was granted an exemption from the 
institutional review board of the University of South Carolina.  
       We used a retrospective cohort to examine the relationship between OCs and breast cancer 
mortality among low-income populations by race/ ethnicity. Women exposed to POCs, COCs, or 
POC+COC are compared to individuals who have never been exposed to OCs. Our study is 
composed of an open cohort, where individuals can leave and enter the population at different 
time points, from 2000 to 2012.  
Study Population 
       Medicaid data consists of an open population limited to individuals with ≥12 months of 
eligibility. The study population included women diagnosed with a histopathologically 
confirmed, first primary breast cancer in South Carolina between 2000 and 2012. Women were 
excluded if they did not have a race designation of EA or AA. Medicaid pharmacy files, classified 
by the National Drug Code (NDC), included information regarding the pill type, date dispensed, 
quantity, and the number of refills. Women with NDC codes with therapeutic class 681200 were 
flagged and women with a prescription for a POC or a COC were included in our study. Women 
using both POC and COC were included in the POC+COC group.  
Covariates  
       To evaluate the association between OC use and breast cancer mortality risk, individual 
baseline and demographic variables were considered in the analysis: year of diagnosis 
(continuous), education (categorical), marital status (categorical), race (categorical), tobacco 
(categorical), duration of pill use (continuous), follow-up (continuous), stage of disease 
(categorical), age (continuous), duration (continuous) and time-to-mortality (continuous). 
Education was categorized as < high school/ some high school/  high school graduate/ ≥ high 
school; marital status: married/ not married; race: EA/ AA; tobacco: yes/ no; duration of pill use 
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(months); follow-up (months); stage of disease: stage 0- in situ/ stage I- local/ stage II- regional/ 
stage III- distant; age (years); duration (months); and time-to-mortality (days). Based on the 
directed acyclic graph (DAG, Figure 1), race and age are confounders, or covariates that create a 
biasing path (Textor et al., 2011). Adjusting for age and race is a minimally sufficient set for 
estimating the direct effect of OC use on breast cancer (Samson et al., 2015; Fleischer et al., 
2008).  
Main Outcome Measurement  
       Breast cancer occurrence was determined according to the International Classification of 
Diseases (ICD-9) codes from the ORS/RFA and SCCCR. Individuals with ICD-9 codes for 
malignant neoplasms of female breast: 174.X; carcinoma in situ of breast: 233.0; and neoplasms 
of uncertain or unspecified behavior (excluding skin of breast): 238.3 and 239.3. The SEER 
staging manual (2000) was used to classify breast cancer as in situ or noninvasive (stage 0), 
localized only (stage I), regional (stage II) or distant sites (stage III). Mortality was determined by 
the SCCCR. Cause of death was categorized as either breast cancer, other, or alive.  
Statistical Methods  
       Descriptive statistics, stratified by OC use, were calculated for all baseline demographic 
variables. All categorical and continuous variables were assessed using chi-square test and two-
tailed t-tests, respectively. The continuous variables are presented by mean (standard deviation 
(SD)) and categorical variables by frequencies (percentages (%)). All P values were 2-tailed, and 
significance was assessed as a Type I error rate of alpha 0.05. Kaplan-Meier survival curves were 
calculated, and the log-rank test statistic was used to assess statistical differences between OC 
groups for breast cancer mortality. Competing risk models were performed and models fitted 
using the Lunn McNeil approach to estimate cause-specific mortality (breast cancer and other 
causes) (Lunn et al., 1995). Associations among all-cause mortality rates, race, and other 
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important covariates were estimated using Cox proportional hazards (PH) model. In the 
competing risk model, events were classified as breast cancer or other cause mortality and in the 
Cox PH model, events were classified as all-cause mortality. Total survival time was calculated 
for all subjects as the time from oral contraceptive use to the time of death or censoring. In the 
Cox PH model, women were followed from OC use until any event occurred (breast cancer or 
other cause) to determine all-cause mortality. In the competing risk models, survival time was 
calculated from OC use to breast cancer mortality and in a separate model, from breast cancer 
diagnosis to non-breast cancer deaths, or other causes of deaths. Women were censored at either 
the date of death for their respective model or at the end of the study period, whichever occurred 
first.  
       Separate competing risk models were performed by race (EA/ AA), adjusting for other 
baseline and demographic variables.  Cox PH models were used to assess the association between 
baseline and demographic variables with hazard risk from overall mortality by race. We evaluated 
PH assumption and the time-dependent relationship between OC exposure and all-cause mortality 
using Cox PH models. In our final competing risk model, we adjusted for OC use, marital status, 
year of diagnosis and age for EA women and OC use, stage, and age for AA women, when 
assessing breast cancer mortality. Duration was not a significant predictor in these models. 
Adjustments varied slightly when assessing other cause mortality by race (Table 2). Covariates 
were determined based on backward elimination with an entry level of 0.10. However, OC use, 
our main variable, was kept in all models based on the a priori research question. In the reduced 
model, the p-value < 0.05 were considered statistically significant. All analyses were performed 
using SAS version 9.4 (Cary, NC).  
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5.4 Results 
Participants  
       Baseline characteristics according to OC use are presented in Table 1. A total of 3,364 breast 
cancer patients diagnosed between 2000 and 2012 were included in the analysis. The OC 
distribution was POC (n= 135; 2.8%), COC (n= 3,958; 82.2%), and POC + COC (n= 265; 5.5%). 
Never users consisted of 9.5% of the study population. The highest mean age (41.5 years (SD: 
8.2)) of use was seen among POC+COC users, a group which primarily consisted of married 
women (80.4%) and women who had more than a high school education. The shortest mean 
follow up was seen among POC users (99.3 months (SD: 43.7)). No women in our sample who 
used POC+COC or POC exclusively were diagnosed with stage III breast cancer.  
       Figure 2 presents the univariable hazard ratios for risk of breast cancer and all-cause 
mortality by race and OC type. The crude analysis suggests an increased risk of breast cancer 
mortality among COC users of all races (HR: 1.80; 95% CI: 1.29, 2.55) and among EA women 
(HR: 2.10; 95% CI: 1.44, 3.06), specifically. The decreased risk seen in AAs using COC is non-
significant (p-value: 0.21). Similar findings were observed among COC users and all-cause 
mortality (all races- HR: 2.38; 95% CI: 1.71, 3.32, EA- HR: 2.85; 95% CI: 1.96, 4.14, AA- p-
value: 0.26). POC was inversely associated with breast cancer-specific mortality among all races 
(HR: 0.04; 95% CI: 0.01, 0.33, p-value: < 0.01) but was not associated with all-cause mortality 
(HR: 0.60; 95% CI: 0.30, 1.20, p-value: 0.28). Competing risks regression analyses that 
controlled for marital status, follow up, year of diagnosis, age, and stage of breast cancer 
diagnosis were performed to assess whether the use of OC was associated with longer survival 
times compared to no OC use. Tobacco and duration were removed in the final model due to 
missing information and nonsignificant findings.  
       Kaplan-Meier survival curves of Medicaid cohort are stratified by their OC exposures (never 
users, POC, COC, or POC+COC) in Figure 3. There are significant differences in survival by OC 
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type. POC users performed worse than never users until approximately 6 years but performed 
better than COC and POC+COC users regardless of timing. As shown in the reduced models 
(Table 2), EA women had a significantly higher likelihood of breast cancer death when using 
either COC (HR: 1.91, p-value: <0.01) or POC+COC (HR: 3.02, p-value: <0.01) compared to 
never use. EA also had a reduction in risk of breast cancer mortality with each additional year of 
diagnosis and age.  OC use was not significantly associated with an increased risk of other-cause 
mortality among EA and AA women and did not significantly decrease the risk of breast cancer 
mortality among AA women. Overall, POC was associated with a reduced risk of breast cancer 
mortality (HR: 0.07, p-value: <0.01) and both COC and POC+COC were associated with 
increased risks of breast cancer mortality (HR: 1.61 and 2.09, p-value: <0.01) (Table 3).  
       Table 4 shows the results of all-cause survival using the Cox PH model for AA, EA, and total 
(AA+EA) women. Overall, OC use was not significantly associated with all-cause mortality 
among AA women. However, without stratification, the total population had an increased 
mortality when using either COCs or POC+COC (HR: 2.19; 95% CI: 1.57, 3.07 and HR: 2.64, 
95% CI: 1.59, 4.39, respectively). The increased all-cause mortality risk was also noted among 
EA women using COCs and POC+COC. EA women and the total population saw 2-3 fold 
increased risk of all-cause deaths among COC and POC+COC users.  
5.5 Discussion  
       In this large study of 4,816 women (4,358 OC users) we found that COC and POC+COC use 
were positively associated with breast cancer mortality. After adjustment for relevant covariates, 
EA women using COCs and POC+COCs had 1.91 to 3.02 times the risk of breast cancer death 
and 2.65 to 3.25 times the risk of all-cause mortality compared with never users. The association 
between AAs OC use and breast cancer mortality was not significant. Mortality in the AA 
population was primarily determined by stage of breast cancer diagnosis.  
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       Recently, a meta-analysis of contraceptive use and breast cancer risk showed POCs were not 
associated with increased breast cancer risk (Samson et al., 2015). In this current study, we found 
a significantly reduced risk between POC use and breast cancer mortality in the total population 
(HR: 0.07; p-value: <0.01). Yet, POCs were associated with non-significantly increased 
likelihood of death from other causes (non-breast cancer mortality) and non-significantly reduced 
risk of all-cause mortality. Other studies have hypothesized that medical surveillance may bias 
the relationship between COCs and breast cancer (Shapiro, 2000; Kumle et al., 2002) and 
similarly, access to health care may bias the relationship between COCs and breast cancer 
mortality. However, this biasing relationship is reduced in our study because POC and 
POC+COC users have undergone similar medical surveillance procedures and have similar 
access to health care. 
       This study suggests that OCs play a differential role in breast cancer, other cause and all-
cause mortality by race. However, the lack of a clear association among AA women using OCs 
and our outcomes of interests requires more attention. Larger sample sizes of AA women may be 
necessary in the future to examine this relationship. There were only six AA women using 
POC+COCs, which reduces our power in interpreting POC+COC utilization in this population. 
Understanding the role of OC types on women’s health could help minimize the burden of cancer 
and more epidemiologic studies need to be done to explore the effect of POCs. The only 
marketed POC in the United States is norethindrone .35 mg tablet, which includes Camila, Errin 
Nor-QD, Ovrette, Jolivette, OrthoMicronor and generic medications. Typically, POCs are 
recommended for women who have certain contraindications to estrogen-containing 
formulations. For example, in our population, smoking was more common among POC users 
(82.4%). Despite 28.7% of COC users being smokers, smoking is a known contraindication of 
COC use and may result in serious adverse events (e.g. VTE, stroke) (FSRH, 2009; FSRH, 2011; 
Curtis, 2010). Most of the available information about the risks of breast cancer focuses on COC 
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users and case-control studies. Comparing various types of contraceptive preparations may 
provide us with insight to safer alternatives to pregnancy prevention, especially among high-risk 
groups.  
       This study should be replicated in more generalizable populations but still provides with us 
with insight to a less risk adverse alternative to COCs. It is important to raise awareness of POCs 
in populations that have large numbers of smokers, family history of breast cancer, and 
cardiovascular disease, and who may be more susceptible to the estrogen component in the OC 
pill. The use of OCs can vary drastically by region. In the US, approximately 17% of women 15-
45 use COCs, which is only half the number of women using OCs in Europe and twice the 
number of women in Africa (Brynhildsen, 2014). Future research should examine this 
relationship by region and using different cohorts.  
Strengths and limitations  
       Strengths of our study include the large sample size and detailed information on medication 
use from enrollment and administrative claims data. Our study did not exclude POC formulations 
when considering types of OCs, which makes it unique. Furthermore, our sample population is 
restricted to Medicaid beneficiaries, which provides us with unique insight to underrepresented 
groups.  However, this data registry did not provide information on potential confounders such as 
diet, physical activity, serum lipids, blood pressure, family history, and other reproductive factors 
(e.g. menstrual history). Limited information was provided on tobacco use. Studies have shown 
that there is a considerable amount of misinformation among health care providers and 
contraception health and that older providers, and primary care physicians tend to demonstrate a 
larger gap (Dehlendorf et al., 2010). 
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5.6 Conclusion  
       Among premenopausal women using OCs, COCs were the strongest predictor of breast 
cancer mortality and POC+COCs were the strongest predictor of overall mortality. The type of 
OC used should be taken into account when assessing breast cancer mortality risk. POCs may be 
a safer alternative for women who may suffer short and long-term adverse events related to the 
estrogen component of COCs.  
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5.7 Tables and Figures 
Table 5.1 Baseline demographic characteristics of Medicaid Participants by 
OC use, 2000-2012 
 
                                                       Oral Contraceptive Types 
Characteristic
s (N, %) 
Never Use  
(n=458) 
POC 
(n=135) 
COC 
(n=3958) 
POC+ COC 
(n=265) 
P  
Value 
Breast Cancer      0.24 
    Yes  342 (74.7) 96 (71.1) 2698 (68.2) 228 (86.0)  
    No 116 (25.3) 39 (28.9) 1260 (31.8) 37 (14.0)  
Race     <0.01 
  White  427 (93.2) 118 (87.4) 3773 (95.3) 259 (97.7)  
  Black   31 (6.8) 17 (12.6) 185 (4.7) 6 (2.3)  
Education      0.31 
< High School 26 (12.2) 14 (53.9) 532 (28) 0 (0.0)  
Some high 
school  
5 (2.3) 0 (0.0) 32 (1.7) 0 (0.0)  
High school 
graduate 
12 (5.6) 2 (7.7) 121 (6.4) 0 (0.0)  
> High school 171 (79.9) 10 (38.5) 1215 (64.0)) 111 (100.0)  
Stage      <0.01 
Stage 0- In situ 17 (5.0) 3 (3.2) 343 (12.8) 22 (9.7)  
Stage I- Local 156 (45.8) 48 (51.1) 1175(44.0) 12(5.3)  
Stage II- 
Regional 
166 (48.7) 43 (45.7) 978 (36.6) 194 (85.1)  
Stage III- 
 Distant  
2 (0.6) 0 (0.0) 178(6.7) 0 (0.0)  
Tobacco      0.31 
Yes  17 (10.9) 28 (82.4) 352 (28.7) 0 (0.0)  
No 139 (89.1) 6 (17.7) 876 (71.3) 16 (100.0)  
Married     <0.01 
  Yes  128 (30.1) 45 (37.2) 992 (25.1) 213 (80.4)  
  No 298 (70.0) 76 (62.8) 2954 (74.9) 52 (19.6)  
 
Mean (SD) 
     
Age  34.4 (5.3) 35.0 (6.7) 36.2 (7.3) 41.5 (8.2) <0.01 
Follow-up  121.9 (15.7) 99.3 (43.7) 139.4 (29.2) 135.7 (21.9) <0.01 
Year 2008.8 (2.4) 2008.1 
(3.2) 
2008.6 (2.8) 2010.0 (1.5) <0.01 
Duration of  
use  
N/A 7.4 (4.4) 40.6 (34.4) 67.9 (43.6) 0.03 
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Table 5.2 Competing Risk Regression Analysis for Death from Breast Cancer and 
Other Causes in Medicaid Patients by Race  
 Breast Cancer Mortality α Other cause Mortality β 
Variable  No. of 
Patients  
No. of 
Events  
Estimate  HR  P-
Value  
Estimate  HR  P-
Value  
European American 
Oral 
Contraceptive 
        
  Never use 427 320 (ref) (ref) (ref) (ref) (ref) (ref) 
  POC 118 82 -12.88 <0.01 0.95 0.07 1.08 0.99 
  COC 3773 2575 0.65 1.91* <0.01 0.08 1.08 0.99 
  POC+COC 259 225 1.11 3.02* <0.01 0.08 1.09 0.99 
Married 
  No  
 
3196 
 
2391 
 
(ref) 
 
(ref) 
 
(ref) 
 
(ref) 
 
(ref) 
 
(ref) 
  Yes  1327 795 0.13 1.13 0.21 -3.95 0.02* <0.01 
Follow-up 
time 
4577 3202 £ £ £ 0.01 1.01* <0.01 
Year of 
Diagnosis 
4577 3202 -0.34 0.71* <0.01 0.69 0.71* <0.01 
Age  4577 3202 -0.04 0.96* <0.01 £ £ £ 
African American 
Oral 
Contraceptive 
        
  Never use 31 22 (ref) (ref) (ref) (ref) (ref) (ref) 
  POC 17 14 -1.49 0.23 0.17 -0.24 0.58 0.82 
  COC 185 123 -0.72 0.49 0.10 -0.55 0.50 0.71 
  POC+COC 06 03 -0.24 0.78 0.82 N/A± N/A± N/A± 
Stage  
  In situ 
 
36 
 
17 
 
(ref) 
 
(ref) 
 
(ref) 
 
(ref) 
 
(ref) 
 
(ref) 
  Local 94 62 1.47 4.34* 0.04 £ £ £ 
  Regional 93 68 2.08 8.04* <0.01 £ £ £ 
  Distant 12 11 3.65 38.50* <0.01 £ £ £ 
Year of 
Diagnosis 
239 162 £ £ £ -0.51 0.60* <0.01 
Age  239 162 0.04 1.04* 0.05 £ £ £ 
α EA: adjusted for OC use, marital status, year of diagnosis, and age; AA: adjusted for OC use, stage, and 
age; β EA adjusted for OC use, marital status, follow-up, and year of diagnosis; AA: adjusted for OC use, 
and year of diagnosis; £ Not included in reduced model (Overall model >0.05); HR: Hazard Ratio; CI: 
Confidence Interval; ± Sample size/ count < 5; *Significant (p< 0.05) 
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Table 5.3 Competing Risk for Breast Cancer Mortality Using the Total Population  
 No. of 
Patients  
No. of 
Events  
Estimate  HR  P-Value  
Oral Contraceptive       
  Never use 916 684 (ref) (ref) (ref) 
  POC 270 192 -2.65 0.07 <0.01 
  COC 7916 5396 0.48 1.61 <0.01 
  POC+COC 530 456 0.74 2.09 <0.01 
*Adjusted for OC use, marital status, stage, follow-up, year of diagnosis, and age; Adjusted for all races 
Table 5.4 Cox regression analysis for overall survival deaths in the Medicaid cohort  
 Race N  Overall Mortality β 
Oral Contraceptives     
Never Use  EA £  427 1.00 
 AA‡ 31 1.00 
 Total ¥ 458 1.00 
POC EA  118 0.92 (0.43, 1.94)  
 AA 17 0.24 (0.05, 1.19) 
 Total  135 0.81 (0.41, 1.59) 
COC EA  3773 2.65 (1.81, 3.86)* 
 AA 185 0.43 (0.19, 1.00) 
 Total  3958 2.19 (1.57, 3.07)* 
POC+ COC EA  259 3.25 (1.89, 5.58)* 
 AA 6 0.33 (0.39, 2.81) 
 Total  265  2.64 (1.59, 4.39)* 
‡ AA satisfied PH assumption, no time-dependent covariates; £EA did not satisfy PH assumption, time-
dependent model covariate (stage) used; ‡Model adjusted for OC use, stage, and year of diagnosis; £ Model 
adjusted for OC use, marital status, year of diagnosis, and (as a function of time) stage; ¥ Model adjusted 
for OC use, marital, follow-up time, year of diagnosis, and (as a function of time) stage  
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Figure 5.1 Directed Acyclic Graph illustrating the association of POC use  
and breast cancer risk  
POC 
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Figure 5.2 Univariable hazard ratios for risk of breast cancer mortality (top) and 
all-cause mortality (bottom) by race and oral contraceptive type 
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Figure 5.3 Kaplan-Meier (KM) Survival Curves (“Time-to-mortality”) for different 
Oral Contraceptive Users (Never Users/ POC/COC/ POC+COC) 
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CHAPTER VI.  
ORAL CONTRACEPTIVES AND CARDIOVASCULAR DISEASE  
6.1 Abstract3 
       Introduction: Certain types of oral contraceptives (OCs) can produce favorable effects on lipid 
metabolism and vascular tone, while others have potentially detrimental effects. Endogenous and 
exogenous hormones exert different effects on high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) depending on the type, combination, and dose of the hormone.  The estrogenic 
and progestogenic effects of exogenous hormones on HDL and LDL are inconsistent. Studying 
surrogate end points (LDL, HDL levels) may provide a misleading picture of OCs.  
       Methods: Medicaid data (2000-13) were used to assess the relationship between the type of 
OCs and CVD incidence. Multivariable logistic regression was used to model relationships between 
cardiovascular disease and OC use adjusting for potential confounders.  
       Results: Compared to combined OCs (COC), progestin-only OCs (POC) decreased heart 
disease and stroke incidence after adjusting for important covariates (OR: 0.74and 0.39, 
respectively; p-value: <0.05). However, POC+COC was associated with a significant increased 
risk of heart disease and stroke incidence (OR: 2.28 and 2.12, respectively; p-value: <0.05).  
      Conclusion: Careful consideration of women’s CVD risk factors should influence choice of OC 
used. Baseline CVD risk should be a part of the discussion between women and their primary care 
providers when making choices regarding OCs.  
                                                     
3 Samson, M., Adams, SA., Zhang, J., Bennett, C., Hebert, JR. (2016) Cardiovascular Disease Incidence among 
Females in South Carolina by Type of Oral Contraceptives, 2000-2013: a retrospective cohort study. Under Revision. 
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6.2 Introduction   
       Cardiovascular diseases (CVDs), including hypertension, stroke, coronary heart disease 
(CHD), peripheral artery disease, and venous thromboembolism (VTE), are the leading causes of 
death among females in the United States (US) (Go et al. 2013; CDC, 2013a). Heart disease and 
its complications are the largest contributors to CVD incidence and mortality (Mosca et al., 2011) 
and disproportionately affect women and African Americans (AA) (Albert et al. 2004). Over the 
past decades, there has been an increased use of oral contraceptives (OCs) (Shufelt et al., 2009), as 
well as significant increase in heart disease and stroke morbidity and mortality rates (Go et al. 
2013). OC use, body fat, and race can lead to lipid and lipoprotein abnormalities and are important 
contributors to CVD (Miller, 1994; Berenson et al., 2009).   
       OCs modulate lipid metabolism differentially according to the hormone make-up (e.g. 
progestin-only, combined estrogen+ progestin), delivery route and the particular patterns of use 
(Crook et al., 1988). High levels of low-density lipoprotein (LDL) cholesterol and triglyceride 
levels increase the risk of CVD in women while high-density-lipoprotein (HDL) may confer 
considerable protection against CVD incidence (Finks, 2015). Hormones may have both beneficial 
and harmful impacts on lipids, lipoproteins, and cardiovascular health. Ideally, women should use 
OCs that reduce their risk of CVDs and protect them from unwanted pregnancies. 
       Endogenous estrogen, or estrogen produced naturally within an individual, can decrease LDL 
and total cholesterol by 5-15% and increase HDL by 10% (Gouva et al., 2004). However, 
exogenous estrogen, which is introduced to the body from an external source, has a diminished 
cardioprotective effect (Rosano et al. 2000). The relationship betweeen hormones and CVD 
becomes more complex when accounting for specific types of estrogen and progestin formulations 
or progestin-only formulations, which vary by country and OC generation (Dumeaux, et al., 2003).  
Exogenous progestins end estrogens have not been studied as extensively and may have no 
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influence on LDL and HDL levels (Chakhtoura et al., 2009; Graff-Iversen, 2015). Thus, focusing 
on surrogate end points alone to predict clinical outcomes may be misleading (Herrington et al., 
2003). Although many pharmacologic agents (e.g., statins, PCSK9 inhibitors) that lower LDL 
significantly reduce cardiovascular events in many individuals, other interventions that increase 
HDL and reduce LDL have no beneficial effect on CVD health (AIM-High, 2011).  
       Additional studies are necessary to understand the role of OCs in the cardiovascular system, 
with a particular focus on progestin-only oral (POC) formulations. Due to the popularity of 
estrogen+ progestin, or combined oral contraceptives (COC), studies have focused mainly on these 
types of OCs and overlooked the action of progestin (or exogenous progesterone) on CHD and 
stroke incidence. We hypothesize that POC users have a reduced risk of CVD compared to current 
and past COC users. Studies have shown COC users are more likely to suffer from VTE, stroke, 
myocardial infarction, cancer, and other chronic diseases (Marchbanks et al., 2002; ACOG, 2006; 
FSRH, 2009) compared to never users. The primary objective of the present retrospective cohort 
study was to compare the effect of COC formulations with progestin-only regimens to understand 
the association of OC types and CVD incidence. We also examined potential effect modification 
by race.  
6.3 Methods  
Setting  
       South Carolina’s (SC) Medicaid population is ideal for studying CVD incidence among 
racial/ethnic groups due to the high percentage of chronic disease, females and AAs in SC 
(Medicaid, 2015). SC is located in the southeastern part of the US, which is often referred to as 
both the “Stroke Belt” and the “Heart Failure Belt.”  This region of the US is known as such because 
of the excess incidence and mortality of strokes and heart failure compared to the rest of the nation  
Montresor-López et al., 2015; Mujib, Zhang, Feller, & Ahmed, 2011; Samson, Trivedi, & Heidari, 
2015). Furthermore, Medicaid is one of SC’s largest insurance providers, insuring 21% of SC 
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residents, of which, 43% are AA (Medicaid, 2015; MLTSS, 2015). There has been significant 
increase in POC use among European American (EA) and AA women in SC from 2000 to 2013 
(Samson, Adams et al., 2015), which will provide us with adequate sample sizes to study the role 
of progestin-only contraceptives on CVD incidence. 
Study Design and Participants 
       We constructed a retrospective cohort from the SC Revenue and Fiscal Affairs Office (RFA) 
Medicaid administrative enrollment and claims data to examine the relationship between OC type 
and CVD incidence among low-income populations by race/ethnicity. The SC RFA has information 
on OC prescriptions and the cardiovascular disease outcome (stroke and HD incidence). All women 
between the ages of 18 and 55 years (i.e., the usual age range for contraception use) with at least 
one type of OC prescription dispensed from 2000 to 2013 were included. All data were de-
identified.  Approval for the usage of this de-identified information was obtained by the University 
of South Carolina Institutional Review Board, as well as the Office of Research and Statistics/ SC 
Revenue and Fiscal Affairs Office.  
Definition of exposure  
       OC status was determined from pharmacy claims that included the drug/generic names, 
dispensed date (month/year), national drug codes (NDC), therapeutic class (681200), age at claim, 
and days supplied. Women with at least one type of OC prescription dispensed during our study 
period and between 18 and 55 years of age (i.e., the range for contraception use) were included as 
OC users in our study. Type of OCs to which women were exposed included progestin-only oral 
contraceptives (POC), estrogen+ progestin or combined contraceptives (COC), and POC+COC. 
POC formulations in our study population included norethindrone only. OC types (POC, COC, and 
POC+COC) are mutually exclusive. Never users, POC and POC+COC users were compared to 
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individuals who used COCs, the most popular OC type. Duration of OC use was calculated in 
months for each member using OCs. 
Definition of outcome 
       The outcome was classified using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) diagnosis codes (50), collected from the each patients 
enrollment period. A primary diagnosis of HD was classified by the subcategory 414.XX. Major 
complications, such as myocardial infarction (410.XX), other acute or subacute forms of ischemic 
HD (411.XX), angina pectoris (413.XX), hypertensive HD, and diseases of pulmonary circulation 
related to HD, and other forms of HD resulted in a woman being flagged for HD. Similarly, primary 
diagnoses of ischemic or hemorrhagic stroke (ICD-9-CM code of ‘430,’ ‘431,’ ‘432.X,’ ‘433.XX,’ 
‘434.XX,’ and ‘436’) (22) were flagged for stroke.  
Other covariates 
       Information on demographics were included, such as race (African American/ European 
American), education (< high school/ some high school/ high school/ > high school), marital status 
(married/ not married), duration of OC use, follow-up time and age. SC Medicaid administrative 
claims data, included women between January 1st, 2000 to December 31st, 2013, who (1) were 
permanent residents of SC during the study period, (2) had ≥ 12 months of Medicaid eligibility (3) 
were between the ages of 18 and 55 years and (4) were either African American/ black or European 
American/ white. Other races accounted for less than 5 percent of our cohort.  
 
Statistical Analysis 
       Univariate and descriptive statistics were calculated for all study covariates. Differences in 
continuous measures were assessed using 2-sample t-tests and categorical measures were assessed 
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using chi-square test. We evaluated the association between OCs and incident CVD using logistic 
regression analysis. Crude and adjusted odds ratios (ORs) were calculated with their corresponding 
95% confidence intervals. There were four levels of exposure (never use, COC, POC, and 
POC+COC). Each group was compared to COC users, our referent group. Models controlled for 
important confounders, including year of diagnosis, age, race, duration of use, and education. 
Potential confounders that changed ORs by > 10% were retained in the final model. Analyses were 
stratified by race based on a priori hypotheses that there may be dissimilar effects by race. All p-
values were two-tailed, and a value of less than or equal to 0.05 was considered statistically 
significant. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).  
6.4 Results  
Study Participants 
       From 2000 to 2013, there were 1,396 incident CVD events (1,219 HD and 175 strokes). The 
mean age of women experiencing stroke (mean: 28.6 (7.5) years) was higher than those 
experiencing HD (mean: 30.1 (8.4)) (Table 1). The mean age of HD incidence for all women was 
higher among POC users (age: 31.4 SD: 8.8) than all other OC age groups (never user: 26.6 (SD: 
7.0), COC: 28.7 (SD: 7.6), and POC+COC: 26.6 (SD: 7.0). Similarly, the mean age of stroke 
incidence for all women was higher among POC (mean: 29.8 (SD: 10.4)) compared to all other 
women (Table 1). 
       Table 2 shows that after adjusting for important covariates, never users and POC users had a 
significantly reduced odds of HD compared to COC users (OR: 0.65; 95% CI: 0.52, 0.82 and OR: 
0.74; 95% CI: 0.57, 0.97, respectively). POC+COC users had a significantly increased risk of HD 
(OR: 2.28; 95% CI: 1.92, 2.70) compared to COC users.  
       OC types conferred similar benefits and harms on both HD and stroke incidence, relative to 
COC users. The decreased risk seen among never users in predicting HD incidence compared to 
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COC users, was consistent among women who had strokes, albeit not significant (OR: 0.95; 95% 
CI: 0.57, 1.59). However, there were differential effects by race. AA women who never used OCs 
had a non-significantly higher incidence of stroke (OR: 1.28; 95% CI: 0.72, 2.27) compared to 
COC users, whereas EA women had a non-significantly decreased risk (OR: 0.46; 95% CI: 0.14, 
1.46).  Overall, POC users had significantly decreased risks of stroke (0.39; 95% CI: 0.16, 0.95) 
compared with COC users.  
       Unlike other OC methods, POC+COC users did not have a protective effect on heart disease 
or stroke risk. After adjusting for important covariates, women using POC+COC had twice the 
odds of heart disease (OR: 2.28; 95% CI: 1.92, 2.70) and stroke (OR: 2.12; 95% CI: 1.34, 3.35) 
compared to COC users. 
6.5 Discussion  
       This retrospective analysis sought to examine the relationship between OC types among a 
population of low-income women and the incidence of heart disease and stroke. Our study findings 
show that POC users have a significantly reduced risk of heart disease and stroke compared to COC 
users. Never users also have a significantly reduced risk of heart disease; however, among stroke 
patients, the risk reduction is non-significant. Despite the non-significant association between never 
users, it is interesting to note that the point estimates for never users were in opposite directions for 
AA and EA women.  
       Among never users, AA women had a non-significantly higher risk of stroke compared to EA 
women (Bousser et al., 2000; Roach et al., 2015; Kemmeren et al., 2002). Also, women had strokes 
at a younger age than expected. These results requires additional attention in future studies. The 
high prevalence of substance abuse in the Medicaid hospital care program (Fox et al., 1995), as 
well as the association between young adults’ abuse of amphetamines or cocaine and increased risk 
of stroke (Westover AN et al., 2007) may have contributed to the unexpected results among 
women. 
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       Other potential explanations for the differential stroke risk by race may be explained by 
environmental or genetic factors, as well as medical surveillance bias (Szklo et al., 2012). AA 
women’s higher risk of stroke incidence and mortality compared to EA women (Bhandari et al. 
2005), may be associated with their higher BMI (Morales et al. 2014), differential lipid modulation, 
thrombophilia occurrence (Greenlund et al., 1997) and the type of OC prescribed. Despite a decline 
in recent decades of CVD mortality in the US, the rate among younger women has plateaued 
(Chomistek et al., 2015). Therefore, it remains critical for us to investigate risk factors for CVD 
and to identify sustainable methods to successfully prevent disease.  
       The current literature examining OCs and CVDs often consider surrogate end points, such as 
glucose tolerance and lipoproteins (Crook et al.,  1988; Miller, 1994; Graff-Iversen, 2015) to 
determine if an association exists. However, OC type and hormone interactions play an important 
role in modulating carbohydrate metabolism and lipoprotein risk factors. Due to the complex nature 
of this relationship, the role of exogenous progestin and estrogen on HD and stroke health is still 
not clearly understood (Miller, 1994). Additional studies need to focus on the cardiovascular health 
benefits of exogenous hormones contained in OCs.  
       Additional medical encounters may reduce stroke risk for high-risk COC users because 
physicians may be detecting subclinical cases or precursors of stroke (e.g. hypertension) (Chasan-
Taber et al., 1996) more frequently than for women who have less frequent clinical exposures. This 
may be more noticeable among AA women because of the known association between race and 
stroke (Longstreth, et al., 2015). Increased physician-patient contact may also help explain why 
women in our sample had such a low mean age of disease incidence and why never users may have 
had more stroke events.   
       There are many barriers to women’s health services (Gelberg et al., 2004). The Patient 
Protection and Affordable Care Act (ACA) has many significant implications for women’s health 
that may help reduce costs related to women’s preventive care services, and that may improve 
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gynecological and reproductive health of low-income women. Future studies should consider the 
impact of ACA and Medicaid expansion on women’s health (NWLC, 2015).  
       The widespread use of COCs may inadvertently ignore the guidelines for OC use. According 
to women who are older than 44 years of age should not use COCs (Longstreth et al., 2015); 
however, in our sample, the majority of women older than 44 were using COCs. Furthermore, 
guidelines do not include women who have switched from COCs to POCs, or vice versa. The 
POC+COC group is a unique group that includes many women who have had to change from COC 
to POCs, potentially due to a CVD event, breastfeeding, or temporary loss of fecundity (FSRH, 
2009); or women who switched from POCs to COCs due to irregular bleeding (CDC 2013b; FSRH 
2009). We found that these women typically had a significantly higher risk of CVD incidence; 
however, additional research needs to focus on this understudied group.  
 
Strengths and Limitations 
       Our study has both strengths and limitations. A major strength is the large sample size, which 
allowed us to investigate racial disparities in CVD risk among OC users in South Carolina. Since 
SC has a high representation of AA residents (RFA, 2015), we were able to assess CVD incidence 
in a multi-ethnic cohort. Another strength of our study is we did not have to adjust for 
socioeconomic status because all women in the Medicaid population are low-income. This allowed 
us to study an underrepresented group. However, a limitation to our study is that we did not have 
information on important factors that may influence CVD incidence including lipoprotein levels, 
diet, BMI and tobacco smoking.  
6.6 Conclusion  
       Our research indicates POCs are associated with a significantly decreased risk of heart disease 
and stroke compared to COCs. High-risk groups should consider POCs as an alternative 
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contraceptive method that may reduce risk of certain cardiovascular diseases. If confirmed, these 
results suggest that careful considerations should be made when prescribing OCs. Determining 
which groups will benefit most from using POCs as their preferred contraceptive method may 
improve clinical CVD outcomes for women. 
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6.7 Tables and Figures  
Table 6.1 Characteristics of Medicaid Population with Heart Disease and Stroke, SC Medicaid Population, 2000-2013 
 Heart Disease  Stroke 
Exposure  
(Cases) 
Never Use 
(n=84) 
POC  
(n=64) 
COC  
(n=898) 
POC+COC 
(n=173) 
Never Use 
(n=17) 
POC  
(n=05) 
COC  
(n=133) 
POC+COC 
(n=22) 
Total Sample 7,604 3,500 51,901 4,729 8,233 3,792 56,578 5,225 
Year          
2000-2001 05 (6.0) 07 (10.9) 84 (9.4) 09 (5.2) 00 (0.0) 00 (0.0) 05 (3.8)) 00 (0.0) 
2002-2003 13 (15.5) 07 (10.9) 97 (10.8) 13 (7.5) 01 (5.9) 01 (20.0) 13 (9.8) 01 (4.6) 
2004-2005 12 (14.3) 07 (10.9) 88 (9.8) 18 (10.4) 01 (5.9) 01 (20.0) 11 (8.3) 02 (9.1) 
2006-2007 7 (8.3) 06 (9.4) 140 (15.6) 32 (18.5) 02 (11.8) 00 (0.0) 14 (10.5) 01 (4.6) 
2008-2009 12 (14.3) 08 (12.5) 140 (15.6) 32 (18.5) 05 (29.4) 02 (40.0) 28 (21.1) 04 (18.2) 
2010-2011 16 (19.1) 14 (21.9) 177 (19.7) 40 (23.1) 04 (23.5) 00 (0.0) 29 (21.8) 06 (27.3) 
2012-2013 19 (22.6) 15 (23.4) 198 (22.1) 40 (23.1) 04 (23.5) 01 (20.0) 33 (24.8) 08 (36.4) 
Race          
EA  28 (33.3) 25 (39.1) 370 (41.2) 67 (38.7) 03 (17.7) 01 (20.0) 57 (42.9) 9 (40.9) 
AA 56 (66.7) 39 (5.4) 528 (58.8) 106 (61.3) 14 (82.4) 04 (80.0) 76 (57.1) 13 (59.1) 
Education          
<HS 26 (31.0) 21 (32.8) 319 (35.5) 56 (32.4) 07 (41.2) 02 (40.0) 47 (35.3) 12 (54.6) 
Some HS  11 (13.1) 06 (9.4) 94 (10.5) 31 (17.9) 00 (0.0) 02 (40.0) 13 (9.8) 02 (9.1) 
HS 
graduate 
11 (13.1) 11 (17.2) 149 (16.6) 24 (13.9) 3 (17.7) 1 (20.0) 28 (21.1) 02 (9.1) 
>HS 36 (42.9) 26 (40.6) 336 (37.4) 62 (35.8) 07 (41.2) 00 (0.0) 45 (33.8) 06 (27.3) 
Marital Status        
Married  22 (26.8) 15 (23.8) 210 (23.8) 49 (28.7) 03 (17.7) 00 (0.0) 24 (18.3) 09 (40.9) 
Not 
Married 
60 (73.2) 48 (76.2) 671 (76.2) 122 (71.4) 14 (82.4) 5 (100.0) 107 (81.7) 13 (59.1) 
Mean (Standard Error) 
Age (y) 26.6 (7.0) 31.4 (8.8) 28.7 (7.6) 26.6 (7.0) 26.1 (5.1) 29.8 (10.4) 27.5 (8.2) 28.9 (7.49) 
Duration (m) N/A 12.2 (33.2) 12.1 (18.3)) 37.8 (76.9) N/A 49.2 (102.4) 11.9 (14.7) 14.7 (11.7) 
HS: High School; Rounding may cause columns not to equal 100 exactly 
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 Table 6.2 Unadjusted and adjusted Odds Ratios of Heart Disease and Stroke by OC 
status: Using Combined Oral Contraceptives (COCs) as the Referent Group  
 Heart Disease  
OR (95% CI) 
Stroke  
OR (95% CI) 
 Unadjusted 
(n=1219±) 
Adjusted£  
(n=1197±) 
Unadjusted  
(n=177±) 
Adjusted£ 
 (n=175±) 
COC  1.00 . 1.00 . 
Never User     
EA   0.62 (0.42, 0.91)* 0.64 (0.44, 0.96)* 0.44 (0.14, 1.40) 0.46 (0.14, 1.46) 
AA 0.89 (0.81, 0.98)* 0.65 (0.49, 0.87)* 1.13 (0.64, 1.99) 1.28 (0.72, 2.27) 
 Total 0.63 (0.51, 0.79)* 0.65 (0.52, 0.82)* 0.88 (0.53, 1.46) 0.95 (0.57, 1.59) 
POC     
EA 0.95 (0.63, 1.43) 0.74 (0.49, 1.12)  0.25 (0.04, 1.80) 0.19 (0.03, 1.38) ¥ 
AA 1.13 (0.82, 1.58) 0.75 (0.53, 1.05) ¥  0.81 (0.30, 2.22) 0.55 (0.20, 1.50) 
Total 1.06 (0.82, 1.37) 0.74 (0.57, 0.97)*  0.56 (0.23, 1.37) 0.39 (0.16, 0.95)* 
POC+ 
COC 
    
EA 1.91 (1.46, 2.48)* 2.07 (1.58, 2.72)* 1.63 (0.81, 3.29) 1.98 (0.97, 4.05) ¥ 
AA 2.36 (1.91, 2.91)* 2.42 (1.94, 3.01)* 1.93 (1.07, 3.48)* 2.21 (1.22, 4.01)* 
Total  2.16 (1.83, 2.55)* 2.28 (1.92, 2.70)* 1.80 (1.14, 2.82)* 2.12 (1.34, 3.35)* 
Referent group: COC (Combined oral contraceptive); POC (Progestin-only oral contraceptive); 
POC+COC (Combined progestin-only method and combined oral contraceptive method); Each oral 
contraceptive group is mutually exclusive; EA (European American); AA (African American); 
Total (All Races); £Adjusted for  age, years, duration of use, marital status, and education; ± total; 
*Significant (p <0.05); ¥ Borderline significant (p < 0.10) 
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CHAPTER VII. 
SUMMARY 
7.1 Conclusion  
The purpose of this dissertation is not to sway the reader into thinking that progesterone-only pills 
are the best solution for all women but to highlight the importance of considering a wider range of 
available oral hormonal contraceptive methods depending on the woman’s individual lifestyle, 
family and medical history, attitudes, and perceptions. Over 100 million women worldwide are 
using oral contraception pills without understanding its mechanism of action, health risks, failure 
rates, costs, contraindications, and common adverse events. With the expansion of the Affordable 
Care Act, and growing support for providing over-the-counter oral contraceptive pills, the 
accessibility of the pill will continue to increase. Despite many changes in the composition of the 
pill, adverse drug events still occur. Albeit morbidity and mortality associated with the pill are 
considered to be low, their existence means that there is still room for improvement (Dhont, 2010). 
      Since POCs are considered similar in effectiveness for preventing unwanted pregnancies as 
COCs, we must make sure women are taking the safest preparations. Despite controversies about 
the proper estrogen dose, or the right progestin to use in conjunction with estrogen, there is some 
consensus in the literature that a reduction in estrogen is safer for women. Preparations that do not 
have estrogen reduce the thrombotic risk of women, myocardial infarction, heart disease, and breast 
cancer. Counselling women about their choice of contraception, in relation to family history, is 
good (Roach et al. 2015). Since only a small number of studies have looked at the risk of progestin-
only contraceptives, it is important for us to remain current on this research. 
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      Europeans have reintroduced certain forms of progestin-only oral contraceptives, notably 
desogestrel-only and levonorgestrel-only methods. The United States should consider expanding 
the types of progestin-only methods to see if these can perhaps reduce the irregular bleedings 
associated with progestin-only methods to make them more favorable among women, especially if 
other studies support the reduced risk associated with POCs. 
       Reduction in cardiovascular and cancer fatalities are of great public health importance. The 
benefits of oral contraceptives may outweigh the risks for a group of women in our society, but a 
large percentage of women are being overlooked. If the majority of women using the pill will have 
increased blood pressure and 5% will develop hypertension, we must determine alternatives that 
will reduce the adverse agent health exposures. Furthermore, low-income women are more likely 
to not have access to effective contraceptive counseling and use a method that is not tailored to 
their needs. This special population is also at higher risk for risk factors and co-morbidities that 
increase the risk of OC adverse events. We must make sure that our guidelines consider the needs 
of underrepresented groups as well as high-risk populations.  To increase research related to these 
groups, increasing public access to underrepresented groups health data to promote disparities 
research is important. This will help policy-makers and health care providers understand what is 
needed for all groups to have access to the same, quality health outcomes.  
       Policymakers have considered making OCs accessible over-the-counter. Since the 
complications related to the estrogen-component of combined oral contraceptives may not be 
teased out, we should consider providing progestin-only contraceptives first. This method may be 
a safer alternative to combined oral contraceptives.  
7.2 Interpretation of Findings  
       COCs significantly decreased among AA women and approached rates of use among EA 
women. POC use increased slightly every year from 2000 to 2013. Furthermore, POCs 
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significantly decreased the risk of heart disease incidence and non-significantly decreased the risk 
of stroke incidence after adjusting for important covariates compared to COCs. In addition, 
compared to COCs, POC+COC did not have a significantly increased risk of stroke incidence. 
Perhaps prescription patterns are slowly changing because of the reduced risk or lack of 
association between POCs and certain chronic diseases. These findings suggest that women using 
POCs have less risk of OC-related adverse events.  
7.3 Suggestions for Future Research  
       Additional research is required to support these findings but POCs may have reduced risk of 
chronic disease incidence and mortality compared to COCs. Switching from POCs to COCs, and 
vice versa is not recommended for now. It is possible that our study was biased with women who 
had adverse health effects related to COCs and therefore had to switch to POCs, therefore biasing 
our results. The majority of POC+ COC users were women who switched from COCs to POCs. 
The reasons are not known but speculations have been made, including breastfeeding, or lots of 
complications related to the estrogen component of OCs. Researchers should study the effects of 
ACA expansion on OC use, and if women are being counseled appropriately to use POCs.  
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